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Abstract  
Menaquinone (MQ) is an important electron carrier for electron transport across the membrane, 
which as a result is essential for energy generation for many bacteria in anaerobic and aerobic 
respiration. MenD (2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate 
[SEPHCHC] synthase) is the enzyme responsible for the first committed step in the classical MQ 
biosynthesis pathway and as such is a central element for investigation into the inhibition of the 
classical MQ pathway. 
The aim of this thesis was to purify a newly developed construct of Smeg-MenD that could have 
the His-tag cleaved, and to use this and MenD enzymes from E. coli (purified in this thesis) and S. 
aureus (obtained purified) to expand upon previous work from the Johnston laboratory 
characterising the MenD from M. tuberculosis. This thesis details the results from two different 
bioanalytical techniques (intrinsic protein fluorescence and differential scanning fluorimetry) to 
probe the MenD interaction with a variety of well-known natural ligands (both allosteric- and 
active-site binders) and a small set of potential inhibitors of the MenD enzyme. 
Differential scanning fluorimetry proved to be the most useful technique for investigation of the 
MenD enzymes, with the small volumes required, ability of replicates, and the broad conditions of 
ligands that were tested proving invaluable from this technique. DHNA, the ligand that binds to 
the allosteric site in Mtb-MenD was found to have an effect on MenD from all three species 
investigated in this work, suggesting the potential for an allosteric site to be present in all MenD 
species. Three of the potential inhibitors screened also displayed potential as inhibitors and warrant 
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Chapter 1. Introduction 
1.1 MenD and Menaquinone Biosynthesis 
Menaquinone (MQ), also known as Vitamin K2, is a small molecule involved in electron transfer 
and consequentially bacterial energy generation. For some bacteria such as Mycobacterium 
tuberculosis (M. tb), MQ is essential as it is the sole electron carrier. Notably, humans do not have 
MQ biosynthesis pathways and instead receive MQ from diet. As such, MQ has been of particular 
interest for drug design to many research groups in terms of the biosynthesis of MQ and the 
proteins responsible for the MQ biosynthesis pathway [1, 2]. 
1.1.1 Menaquinone Biosynthesis 
Menaquinone is a lipid-soluble molecule that resides in the bacterial membrane. The structure of 
MQ is comprised of a naphthoquinone head group and an isoprenyl tail, which varies in length 
and saturation dependent on bacterial species [3]. For Gram positive bacteria, MQ with 7 to 11 
isoprenoid residues (MK-7 – MK-11) are considered critical lipid-soluble electron carriers. MQ is 
the sole quinone for Gram positive bacteria and mycobacteria and as such is essential for survival 
[2]. As shown in Figure 1, MQ (MK in Figure 1) transfers two electrons from the electron donor 
to the electron acceptor. The flow of electrons across the membrane causes proton build-up that 
cross the lipid bilayer via ATP synthase travel. This movement causes ATP synthase to produce 
ATP from ADP and phosphate due to a proton motive force production [2]. Humans neither make 
MQ or use MQ in electron transport chains. MQ instead is used in human blood coagulation using 
MQ-4 (Vitamin K2) as a cofactor for vitamin K-dependent proteins like γ-glutamyl carboxylase, 
which is responsible for catalysing the carboxylation of glutamic acids in numerous blood 
coagulation related proteins [2]. Humans receive the MQ-4 they use primarily from conversions 
of MQ-7-15 found in their diet. This mainly is from phylloquinone-containing plants but can also 
be from meat, eggs, and dairy products. Additionally, gut bacteria are also a potential source [4]. 
The tail group of the MQ are converted while the headgroup is not made. Based on this knowledge, 
the menaquinone biosynthesis pathway is highlighted as an ideal drug target due to its absence in 
humans and the reduced likelihood of detrimental effects upon humans in that regard.  
2 
Figure 1: Top: The electron flow system of M. tb. The menaquinone mediated pathway is highlighted in 
blue. Electrons are carried between the membrane proteins via MK. Protons are pumped out of the cell 
and back through the ATP synthase to allow ATP generation. Bottom: The structures of reduced and 
non-reduced menaquinone. The menaquinone in M. tb is most commonly composed of nine isoprenoid 
residues in its ‘tail’. (Image taken from ([5]). 
 
MQ has two potential pathways of synthesis, the futalosine pathway and the classical (Men) 
pathway. It is uncommon for bacteria to have both pathways [6]. The distribution of these 
pathways in human gut microbiome show half of the quinone biosynthesis is through the Men 
pathway. Ubiquinone and futalosine pathways only account for 9% and 5%, respectively [6]. M. 
tb utilises the Men pathway for MQ biosynthesis. The Men pathway was initially thought to be the 
only pathway for MQ synthesis. The Men pathway generally involves 8-10 genes, of which six 
are identified as essential [7]. These resulting enzymes are named as MenA to MenJ, though as 
shown in Figure 2, the order of these enzymes in the pathway is not alphabetical. These enzymes 
are required to produce menaquinone from chorismate [2, 8, 9]. The full Men pathway can be seen 
in Figure 2. The focus for work on the Men biosynthesis pathway has been primarily upon the 
Gram-negative bacteria E. coli as a model. Unlike Gram-positive bacteria, E. coli and other Gram-
negative species make both MQ and ubiquinone, as they are not sole quinone users. There have 
been nine men genes identified in the E. coli model, of which six are also found in M. tb. These 
six genes encode the proteins MenA, MenB, MenC, MenD, MenE, MenG/UbiE. For this work, 
the protein of the most interest is that which performs the first committed step in the pathway, 
MenD [6, 10]. 
3 
 
Figure 2: The classical biosynthesis pathway of menaquinone. The classical pathway begins with 
chorismate as the substrate and through the enzymes MenF, MenD, MenH, MenC, MenE, MenB, MenI, 
MenA and MenG synthesise menaquinone as the final product. Highlighted in green is the first 
committed step, catalysed by MenD, the conversion of isochorismate to SEPHCHC. (Diagram adapted 
from [10]). 
4 
1.1.2 MenD  
2-Succinyl-5-enolpyruval-6-hydroxy-3-cyclohexene-1-carboxylate (SEPHCHC) synthase 
(MenD) is the enzyme responsible for catalysing the first committed step in the classical MQ 
biosynthesis pathway. Originally thought to be responsible for forming 2-succinyl-6-hydroxy-2,4-
cyclohexadiene-1-carboxylic acid (SHCHC) from isochorismate and 2-ketoglutarate, MenD 
instead was found to be a highly efficient enzyme for SEPHCHC synthesis and determined as 
essential for MQ synthesis [11]. As MenD is known to catalyse the first committed step, the 
interest in this enzyme as a potential drug target is significant and several groups are currently 
working with MenD as such [11, 12]. 
MenD is a member of a family of thiamine diphosphate (ThDP)-dependent decarboxylase enzymes 
[12]. All members of the ThDP-dependent decarboxylase enzyme family bind ThDP in a divalent 
metal ion-dependent manner, share a common protein fold, and catalyse the decarboxylation of a 
2-oxo acid. The second step of the reaction for this enzyme family deviates between enzymes, and 
ranges from ligation to a second substrate, protonation, oxidative/reductive processes, carbon-
carbon bond formation, and more [12]. All reactions undertaken by this family of enzymes are 
mediated by the ThDP cofactor, which forms several intermediates along the reaction cycle as 
shown in Figure 3.  ThDP mediation of these enzymes occurs through conformational changes of 
ThDP upon binding to the enzyme. With this shift in the conformation, ThDP is ‘activated’ and 
capable of reacting in the first decarboxylation step. As can be seen in Figure 3, both steps from 
intermediate I and intermediate II require involvement of the cofactor ThDP. ThDP is thought to 
have resonance capabilities in the aminopyrimidine ring, which is observed throughout the 
reaction cycle [13]. 
5 
MenD, like all ThDP-dependent enzymes, catalyses the decarboxylation reaction of a 2-oxo acid, 
which for MenD is α-ketoglutarate. In this thesis it will instead be referred to by its alternative 
name 2-oxoglutarate [12]. The second step of the MenD catalysed reaction is of interest due to the 
unique formation of a new carbon-carbon bond with the substrate isochorismate. This carbon-
carbon bond is formed between the decarboxylated 2-oxoglutarate and isochorismate through a 
Stetter-like 1,4 addition [14]. The MenD reaction cycle is shown in Figure 3. The first step of this 
cycle involves activated-ThDP and 2-oxoglutarate. ThDP reacts with 2-oxoglutarate to form a 
ThDP adduct, which then decarboxylates forming the first covalent intermediate (Intermediate I). 
It is thought that this intermediate is in resonance between the enamine and carbanion forms [11, 
12, 14]. The second step, a Stetter-like 1,4 addition, involves a 1,4 addition of isochorismate to 
Intermediate I. This occurs via nucleophilic attack from the anionic carbon found on intermediate 
I and forms a carbon-carbon bond and thus the second intermediate (Intermediate II).  Finally, 
cleavage of the product SEPHCHC from Intermediate II occurs in the second part of the reaction. 




Figure 3: MenD reaction cycle for SEPHCHC formation. MenD binds and activates ThDP for attack and 
binding of 2-oxoglutarate (bottom right) for decarboxylation. The first covalent intermediate is then 
formed and undergoes the second reaction step with binding of isochorismate for a Stetter-like 1,4 
addition at the thiazolium moiety (blue box) of Intermediate I to form Intermediate II. Cleavage results in 
release of SEPHCHC from Intermediate II while ThDP is recycled. In the green boxes are the retained 





Mycobacterium tuberculosis is the bacterium responsible for the human disease tuberculosis (TB). 
As of 2017, TB was the leading cause of death from an infectious disease. This statistic is greater 
than for HIV, which coincidentally can amplify the fatality rate from TB infections (Figure 4) [16]. 
 
Figure 4: Graph from Global Health Data Exchange of TB and HIV/AIDS deaths over the past 27 years. 
 
Tuberculosis is a highly contagious disease transmitted via inhalation of the bacterium expelled 
by someone with the active disease, resulting in either an active or latent M. tb infection [17, 18]. 
For infection the inhaled tubercle bacilli must first reach the alveoli (air sacs of the lungs) of the 
host, survive being phagocytised by the immune system and then start replicating in the host 
macrophages [19]. This is especially important to the infection as this allows the bacilli to diffuse 
to nearby cells, which drastically increases the population of the bacteria [20]. The bacilli can also 
spread from the lung to other organs of the body for further replication before auto immune 























Table 1: World Health Organisation Classification of anti-TB 
Group Drugs 
Group 1 – first line agents (oral) 
Group 2 – injectable agents 
Group 3 – Fluoroquinolone group 
Group 4 – Other, second line agents 
(bacteriostatic) 
Group 5 – Agents of uncertain efficacy (not 
routinely recommended) 
Isoniazid, rifampicin, ethambutol, pyrazinamide 
Streptomycin, amikacin, kanamycin, capreomycin 
Moxifloxacin, ofloxacin, levofloxacin, gatifloxacin 




 Source: Guidelines for the programmatic management of drug resistant tuberculosis: emergency update[22] 
The current understanding of TB infection proposes that the main difference between latent and 
active forms of TB are based on the presence of a dynamic equilibrium between bacilli and host 
immune responses. If these are in equilibrium the disease remains in the latent form as the 
replicating bacilli, known as ‘scouts’, are constantly killed by the immune system [23]. If for any 
reason the immune system fails to control these scouts, the replication will lead to the active 
disease [24].  The active form of TB is responsible for the high mortality of this disease (~2 million 
deaths/year), with the results of untreated TB being lesions forming in the airways and tissue 
breakdown, among other complications [25]. However, the ability to form the dormant state inside 
the body classified as Latent Tuberculosis Infection (LTBI), effectively ‘hiding’ until the situation 
becomes more favourable, is what makes TB extremely difficult to fully destroy [26]. The World 
Health Organisation has estimated that one third of the world’s population is infected by the latent 
form of the disease, and while the latent form is not infectious it forms a reservoir of infection and  
~10% of those latently infected will develop active TB during their lifetime [24, 27]. One of the 
challenges for new therapeutic developments and research into TB treatment is to focus not only 
on active TB, which already has many treatments, but on the latent form; to fully destroy the 
disease in the population so there can be no risks of the disease reappearing in former patients. 
Active tuberculosis is generally treated by using a variety of drugs consisting of isoniazid (H), 
rifampicin (R), ethambutol (E) and pyrazinamide (Z) for six months (Table 1, 2). This treatment 
regimen is useable for both pulmonary and non-pulmonary TB with the only exceptions being to 
the central nervous system, bone and miliary (throughout the body) TB [28]. The latent form is 
not susceptible to these drugs that kill actively growing TB bacteria, and this makes it a challenge 
to successfully treat. In New Zealand, the most common method to attempt to treat LTBI is through 
an ongoing dosage of isoniazid for 6 to 9 months [29]. Even in active disease cases, a 
subpopulation is likely in the LTBI state, which results in longer treatment times overall. These 
longer treatment times include further adverse side effects and more chance for treatment non-
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compliance and the development of drug resistance [30, 31]. Another challenge to tuberculosis 
eradication is drug resistant and multi-drug resistance infections as different infections can become 
resistant to one or several of the initial drugs provided for treatment. Drug resistant TB results in 
a modified version of treatment for TB consisting of different drug dosages and durations of 
treatment but can generally be worked around. 
Multi-drug resistant TB is a form which is resistant to the two most important TB drugs, rifampicin 
and isoniazid, and requires at least 18 months of treatment with at least four drugs that a patient 
has not already been exposed to and to which the TB is susceptible. While still treatable, it is much 
more difficult to do so and is overall a much more uncertain time for the patient based upon the 
types of drugs they will be treated with. 
Table 2: Suggested regimens for mono- and poly-drug resistance 




H ( S) R, Z and E 6-9 
H and Z R, E and fluoroquinolones 9-12 
H and E R, Z and fluoroquinolones 9-12 
R H, E, fluoroquinolones plus at least 2 months of Z 12-18 
R and E ( S) H, Z, fluoroquinolones plus and injectable agent for at 
least the first 2-3 months 
18 
R and Z ( S) H, E, fluoroquinolones plus an injectable agent for at 
least the first 2-3 months 
18 
H, E, Z ( S) R, fluoroquinolones plus an oral second-line agent, 
plus an injectable agent for the first 2-3 months 
18 
Source: Guidelines for the programmatic management of drug resistant tuberculosis: emergency update[22] 
In all cases, the side effects from these treatments are less than ideal, with gastrointestinal side 
effects being a major factor in standard treatment as well as potential nerve damage (Table 3). In 




Table 3: Adverse effects of tuberculosis drugs 




Ototoxicity (lowest incidence with streptomycin); renal damage, 
skin rashes, fevers, circum-oral paraesthesiae, neuromuscular 
blockade 
Para-amino-salicylic acid Gastrointestinal effects, hepatitis, fever, rash and 
hypothyroidism 
Cycloserine Dose-related central nervous system effects (drowsiness, 
vertigo, disorientation, confusion, coma and psychosis) 
Ethambutol Optic neuropathy (dose-related); peripheral neuropathy, 
arthralgia or rash are rare 
Ethionamide Gastrointestinal effects, liver toxicity; rarely hypothyroidism, 
hypotension, hypoglycaemia, alopecia, convulsions and 
neuropathy 
Fluoroquinolones Gastrointestinal disturbances, dizziness, anxiety, depression, 
confusion and convulsions; rarely, achilles tendon rupture, 
arthropathy and photosensitivity. 
For use in children, consult a paediatric tuberculosis expert. 
Isoniazid Isoniazid hepatotoxicity: Hypersensitivity reactions are unusual. 
Peripheral neuropathy, optic neuritis, fever, hepatitis, ataxia, 
euphoria, convulsions, tinnitus, insomnia, hyperglycaemia, 
gynaecomastia, dry mouth, epigastric discomfort, urinary 
retention, anaemia, arthralgias. Contraindicated in manic states 
and porphyria. 
Idiosyncratic reactions may include a (usually reversible) lupus-
like syndrome (fever, arthritis, pleuritis, pericarditis, positive 
rheumatoid factors, etc), and, very rarely, a rheumatoid arthritis-
like syndrome, and agranulocytosis. 
Very rare hypersensitivity reactions include eosinophilia, 
angiitis, toxic psychosis, and meningo-encephalitis. 
Toxic doses decrease the synthesis of the inhibitory 
neurotransmitter gamma aminobutyric acid. 
Central nervous system depression or stimulation may result. 
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Pyrazinamide Gastrointestinal side effects, hyperuricaemia, hepatotoxicity, 
fever, anorexia, nausea and vomiting; precipitation of gout, 
arthralgias, urticaria, sideroblastic anaemia. 
Of the TB drugs, pyrazinamide is the most common cause of a 
rash. 
Rifabutin Rash, gastrointestinal disturbance, neutropaenia; uveitis, 
particularly in combination with macrolide antibiotics 
Rifampicin Gastrointestinal disturbance, cholestatic hepatic dysfunction, 
transient elevation of hepatic enzymes. 
Danger with intermittent therapy: flu-like syndrome, shock, 
acute renal failure, death. Acute haemolytic anaemia. 
Rare reports of rifampicin-induced light chain proteinuria and 
renal failure, attributed to dehydration associated with fluid 
restriction for syndrome of inappropriate antidiuretic hormone. 
Thiocetazone Nausea, vomiting, diarrhoea, bone marrow depression, vertigo, 
ataxia, tinnitus, occasional liver toxicity, cutaneous 
hypersensitivity. 
Source: Winter et al. (1984)[32] 
New Zealand is part of the World Health Organisation “End TB strategy”, which aims to end the 
TB epidemic globally by 2035 and achieve full elimination by 2050 [33].  While New Zealand has 
a low overall rate of TB infection, certain groups are disproportionately affected such as Maori 
and Pasifika, people with diabetes, and those in lower socioeconomic groups [34, 35]. In addition, 
treatment of TB cases has been shown to be a significant cost to the New Zealand health system, 
due to the cost and duration of the treatment plus the added time and cost for treatment of 
multidrug-resistant strains, and the challenges of effectively treating the latent form of disease [36, 
37]. In 2006, one student from Palmerston North Boys’ High was discovered to have the active 
form of TB, which then led to the infection of 206 others with 18 being other active cases of TB 




1.2.2 Mycobacterium tuberculosis MenD and Prior Work 
Mtb-MenD has been purified and a variety of X-ray crystallography structures with different 
ligands bound have been solved.  Similar to other ThDP-dependent enzymes, Mtb-MenD is 
comprised of three domains each with β-sheets sandwiched between α-helices (Figure 5, a). The 
first and third domain have very similar topology, with both consisting of six-stranded parallel β-
sheets sandwiched between several α-helices. The main difference between these two domains is 
found in a loop linking equivalent β-sheets. In domain III a different orientation is observed, as 
are additional secondary structure elements and a longer length when compared to domain I. 
Domain II, the central domain only has five-stranded parallel β-sheets with six α-helices. In terms 
of binding responsibility, domain I binds the aminopyrimidine ring while domain III binds the 
diphosphate group of ThDP. Both domains are highly conserved in ThDP-dependent enzymes. 
Domain II in some enzymes binds a nucleotide for either structural or allosteric regulatory 
purposes depending on the enzyme [39]. Domain II does not participate in either cofactor or 
substrate binding nor is it heavily conserved [15]. Mtb-MenD has a tetrameric structure in solution, 
which is formed from a dimer of dimers (formed from chains A and D and B and C) [15, 40]. 
Domain II of Mtb-MenD has been recently reported to have an allosteric regulatory site and be 
subject to allosteric regulation, which has not been reported for any other MenD enzymes to date 
[41]. This allosteric site is located approximately 15-20 Å from the nearest active site formed by 
domain III of the same monomer. It is also found approximately 30-40 Å away from domain I as 
well. This allosteric site has been identified to tightly bind the product of MenI; 1,4-dihydroxy-2-
napthoate (DHNA). DHNA appears to provide negative feedback to the MQ biosynthesis cycle. 
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Figure 5: Structural views of Mtb-MenD. Left (a): The Mtb-MenD monomer with domains I, II and III 
shown in purple, yellow, and pink, respectively. The long link between domains I and II is shown in red. 
ThDP is shown bound in green. Right (b): Surface representation of the MenD tetramer. The residues 
from the four different monomers responsible for forming the active sites are coloured in orange, red, 
blue and white. The inset shows a closer look at one of the active sites in the tetramer with ThDP bound. 
The hydrogen bonds between the residues and the co-factor ThDP are shown. 
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Most of the prior work done by the Johnston group has focused on Mtb-MenD. As such the 
information concerning Mtb-MenD has primarily been provided by this group, including the 
allosteric site discovery [15, 41]. It is known that how the active site of MenD functions as ThDP 
anchors into the active site by domain III in the C-terminal through the divalent metal ions and the 
diphosphate part of ThDP. Glu55 along with Ile404, Ala402 and His445 all play key roles at the 
active site to hold ThDP in position as well. Glu55 is the key residue in the activity of MenD as 
when in the active state, the interaction with His445 and the pyrimidine group of ThDP are 
essential for the ThDP activation [15]. Once 2-oxoglutarate has bound and been decarboxylated, 
intermediate I can be formed by hydrogen bond formation between the carboxylate group of 
intermediate I and Arg381 and Arg399. Highly conserved residues found in domains I and III of 
the opposing monomer (Gln 118, Thr78, Arg107, Arg282, and peptide groups of Ser29 and Arg30) 
allow the binding of isochorismate to the enzyme, and consequentially the formation of 
intermediate II. This structural information provided invaluable progress towards inhibitor 
substrate design and production. In addition, the production of crystals which capture the reaction 
at various stages were also successfully created. Visualising these crystals via crystallography 
techniques provides inhibitor binding information, which can help for determining the 
effectiveness of potential inhibitor compounds to MenD. As mentioned previously, Mtb-MenD 
was discovered during this work to have an allosteric binding site in domain II. As this allosteric 
site binds to the product (DHNA) from an enzyme further along the MQ biosynthesis pathway, a 
negative feedback loop to MenD activity is provided via this interaction. The distribution of this 
allosteric site is currently unclear, conservation of key residues is only seen in mycobacteria and 
closely related bacteria however a number of key residues are conserved across a broader 
distribution of species [41]. The presence of this allosteric site has become of interest for drug 
discovery, with prior work investigating potential inhibitors capable of manipulating this allosteric 
site. Prior work revealed several compounds which bound similarly to either the 
substrates/intermediates for MenD or the allosteric regulator of Mtb-MenD. This was proven 
through X-ray crystallography work and these compounds showed potential for further inhibitor 
design. Because of the ease of access to these commercially available compounds, these were 
purchased and used in this work. This project aims to do two things. Firstly it aims to check the 
presence of absence of DHNA (the allosteric regulator) binding in MenD of different species (E. 
coli, S. aureus and M. smegmatis) all of which have varying levels of conservation of the allosteric 
site (very little in E. coli to some conservation in S. aureus to very similar in M. smegmatis). 
Secondly it will continue with the inhibitor work previously achieved, through the testing of these 
potential inhibitor compounds to these three MenD enzymes from different species. Seven 
compounds similar to the natural allosteric binder of Mtb-MenD will be tested.  The three enzymes 
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under investigation in this work will be called Sau-MenD (S. aureus), Smeg-MenD (M. smegmatis) 
and Ec-MenD (E. coli). 
1.3 Characteristics of MenD Species 
1.3.1 DHNA Binding Capabilities 
1.3.2 Escherichia coli 
E. coli is the most prolific and well-known pathogen in the world. Many E. coli species are 
commensal and live on humans and many other animals without any effect on the host. Most 
commonly found in the intestines of vertebrates, E. coli is an incredibly versatile pathogen with 
an extremely large population size of 1026 [42]. An incredibly accessible pathogen, E. coli is one 
of the best characterised model organisms, with many strains of E. coli being responsible for 
advancements in almost all fields of biology (genetics, molecular biology, physiology and 
biochemistry). This is in no small part due to the diversity found in the E. coli population [43]. 
As such, E. coli has also had major contributions to the understanding of the MQ biosynthesis 
pathway despite having very minor reliance upon this pathway. E. coli is the only Gram-negative 
bacterium investigated in this work, and as with all Gram-negative bacterium’s preferentially 
utilises ubiquinone in aerobic conditions, only utilising MQ in anaerobic conditions [44]. MQ is 
still synthesised in Gram-negative bacteria, and as such can still be incredibly useful for 
investigating conserved residues and domains as well as inhibitor investigation for enzymes in the 
classical pathway. The structure of Ec-MenD and many of the other Men enzymes have been 
solved already, with no allosteric site activity tested for or considered previously in Ec-MenD [40]. 
This work has chosen to include Ec-MenD as a research enzyme due to its ease of access and how 
well studied it has been.  
Extensive research has been conducted upon the E. coli menaquinone pathway and as such, Ec-
MenD. This research includes identification of essential conserved residues in the MenD enzyme 
active site, determination of successful techniques for characterising and assessing the activity of 
the MenD enzyme, particularly with interactions between ThDP and MenD and reclassification of 
the function of the MenD enzyme in the Menaquinone synthesis pathway [45-49].   Previous 
research has successfully solved structures of Ec-MenD in both apo and cofactor bound states [40]. 
As with all ThDP-dependent enzymes, Ec-MenD forms dimeric and tetrameric structures due to 
the active site and cofactor binding sites being found from contributions by at least two subunits. 
As mentioned by Dawson et al., Ec-MenD’s predominant structure appeared to be a dimer, with 
smaller tetramer quantity present while in solution, however a mixture of monomer, dimer trimer 
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and tetramer was observed in solution, yet  the structures remain consistently tetrameric [40]. It 
also appears that the presence of cofactor (ThDP and/or Mn2+) induce significant conformational 
changes in the protein. The Ec-MenD subunit is shown to display the typical three-domain 
architecture expected of ThDP-dependent enzymes [40, 50] (Figure 6, a).  Again, domain I is 
responsible for binding the aminopyrimidine ring of ThDP and helping form the active site, while 
domain III binds to the diphosphate group of ThDP and is also responsible for forming the active 
site. In the case of Ec-MenD, dependency on domain II is non-existent due to stabilization effects 
being observed elsewhere [40]. Domains I and III are responsible for the formation of the Ec-
MenD dimer, whereas domain II plays a more significant role in the formation of the tetramer. The 
active site of Ec-MenD is formed from contributions from two subunits. The active site contains 
five arginine residues (Arg33, Arg107, Arg395 from chain A, Arg293 and Arg413 from chain B) 
as well as a lysine residue (Lys292) from chain B. Lys292 and Arg293 are both uniquely found 
further from the catalytic site than the other residues, located in domain II. Arg293 is not well 
conserved between MenD enzymes and is unlikely to bind any substrates directly, however it is 
thought to contribute to the active site in Ec-MenD. The active site also contains a hydrophobic 
patch created by the side chains of Ile474, Phe475 and Leu478 from chain B, all of which are 
strictly conserved in MenD enzymes. Of the most importance in the active is the glutamine residue 
(Glu55). This residue is strictly conserved and it has been observed that mutagenesis of this 
residues results in no activity of the Ec-MenD enzyme at all [51]. 
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Figure 6: Structural views of Ec-MenD. Left (a): Diagram of the Ec-MenD subunit highlighting the 
three domains involved. Domain I is in blue, Domain II in yellow and Domain III in green. The long 
linker between Domains I and II is shown in red. Right (b): The Ec-MenD Dimer with ThDP bound at 
each active site. The residues responsible for forming the active sites from monomer A are coloured in 
red while the same residues in monomer B are in yellow. A closer look at one of the active sites is shown 
below with the residues responsible for binding to ThDP labelled and the hydrogen bonds shown. 
 
1.3.3 Mycobacterium smegmatis  
Another Gram-positive bacterium, M. smegmatis is generally used as a model for M. tuberculosis 
due to the high similarity between these bacteria [52]. M. tuberculosis enzymes are also frequently 
transformed into M. smegmatis cells to ensure similar activity to wild-type M. tuberculosis. M. 
smegmatis is described as non-pathogenic as it does not enter epithelial cells, does not persist in 
professional phagocytes and has none of the described pathogenic properties found in M. 
tuberculosis [53]. M. smegmatis and M. tuberculosis are both members of the Mycobacterium 
family and are very similar in sequence comparisons, with an 80% identical protein sequence 
between these proteins, including all the key allosteric site residues conserved between the two 
enzymes. The structure of Smeg-MenD has yet to be solved. Due to the relevance in disease 
treatment of Mtb-MenD, understanding the allosteric regulation of Smeg-MenD is, similarly to 
Sau-MenD, a focus for the Johnston research group.  
1.3.4 Staphylococcus aureus 
S. aureus is a Gram-positive bacterium known for its long history with humans in the form of a 
variety of diseases including pneumonia and toxic shock syndrome [54-56]. It is incredibly capable 
at being infectious, boasting an arsenal of toxins and virulence determinants allowing it to infect 
almost every organ in humans. This consequentially results in high morbidity and mortality rates 
of S. aureus infections. In addition to this, antibiotic resistant strains of S. aureus are becoming 
more widespread, demanding more need for new therapeutic target identification [54, 56].  
S. aureus as a Gram-positive bacterium like M. tuberculosis meaning that the sole quinone used 
for electron transport and subsequentially respiration is MQ [8]. As such, the pathway of MQ 
biosynthesis for S. aureus is of particular importance to this work as various similarities could be 
present between Sau-MenD and Mtb-MenD that cannot be observed in the Gram-negative model 
created from Ec-MenD. S. aureus does in fact utilise the classical Men pathway for MQ 
biosynthesis, utilising at least eight of the same enzymes found in M. tuberculosis. Previous 
research from other groups has already proven that disruption of the MQ biosynthesis pathway can 
lead to successful resolutions of other diseases/conditions, such as haem toxicity, suggesting the 
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potential of this pathway as an effective treatment site [57]. Previously, MQ has been identified as 
the sole quinone used for respiration in S. aureus, it is the only quinone responsible for donating 
electrons to the haem molecules in the cytochromes, which S. aureus is known to possess two 
classes of similar to the model organism Bacillus subtillus [58, 59].  The structure of Sau-MenD 
has not yet been solved but is currently under investigation by other members in the Johnston 
group. As such, investigating if the allosteric site found in Mtb-MenD is conserved in this species 
is a high priority. 
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1.4 Objectives of The Study 
The purpose of this work was to further characterise the interactions of MenD enzymes Sau-MenD, 
Ec-MenD, Smeg-MenD with a range of potential ligands using two main methods, intrinsic 
fluorescence quenching (IFQ), and differential scanning fluorimetry (DSF). Previous work with 
Mtb-MenD has utilised both an intrinsic fluorescence binding technique and DSF. Previous DSF 
experiments however focused upon a different set of potential ligands and only investigated the 
binding in relation to Mtb-MenD. This work will investigate binding of the natural ligands of Mtb-
MenD upon the different MenD enzymes as well as the binding of seven different potential 
inhibitors (six of these known Mtb-MenD allosteric binders and one from the active site). The 
intrinsic fluorescence binding assay conducted in previous work used a different experimental 
technique than in this study. A 96-well microplate was used to investigate the quenching of each 
compound. Both these methods can be used to characterise ligand and protein interactions and can 
give different levels of information (with different advantages and disadvantages) and the goal 
was to use them with each protein and find any similarities between different MenD enzymes in 
terms of active and allosteric sites interactions with co-factor ThDP, substrates, DHNA and a small 
subset of the known inhibitor candidates. 
The specific objectives of this research are: 
Objective 1: Purify Ec-MenD and a new TEV cleavable construct of Smeg-MenD in large enough 
quantities and of sufficient purity for further work.  
Objective 2: Use these two enzymes in conjunction with Sau-MenD (purified by Dr Tamsyn 
Stanborough) in IFQ experiments to analyse the interactions with known ligands (ThDP, 2-
oxoglutarate and DHNA) in various combinations to compare and contrast binding properties 
across species. 
Objective 3: Use these two enzymes in conjunction with Sau-MenD (purified by Dr Tamsyn 
Stanborough) in DSF experiments to analyse the interactions with known ligands (ThDP, 2-
oxoglutarate and DHNA) in various combinations as well as with a small set of known Mtb-MenD 




Chapter 2. Methods and Materials 
2.1 MenD Constructs Used in this Study 
2.1.1 pET19 Ec-MenD 
The pET19 Ec-MenD plasmid was obtained from Prof. Michael Mueller’s group in Germany. The 
pET19 vector (Figure 7) contains an ampicillin resistance region (AMP), which allows for 
selection of cells that have successfully incorporated the plasmid, both an AmpR and lac1 promoter 
region for the expression of the target protein, several restriction sites to incorporate the gene into 
the plasmid, and a His-tag on the N-terminal side. 
 
Figure 7: pET19 vector map highlighting features of interest (His-tag, AmpR, Lac1 region). Vector map 
created in SerialCloner. 
22 
2.1.2 pET30a Sau-MenD 
The pET30a Sau-MenD plasmid was made previously by Dr Tamsyn Stanborough in our 
laboratory. The pET30a vector (Figure 8) contains a kanamycin resistance region (KAN) which 
again allows selection of cells that have incorporated the plasmid, a T7 promoter region for target 
protein expression, and a His-tag on both the N-terminus and C-terminus. The N-terminus also 
contains a thrombin cleavage site. 
 
Figure 8: pET30a vector map highlighting features of interest (KAN resistance region, T7 promoter 
region, His-tags, Thrombin cleavage site). Vector map created in SerialCloner. 
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2.1.3 pYUB28b-TEV-smegMenD 
pYUB28b-TEV-smegMenD was made previously by Dr Tamsyn Stanborough in our laboratory. 
pYUB28b-TEV vector is based upon the pYUB28b vector so is structurally identical with one 
exception. The pYUB28b vector was made by Dr Ghader Bashiri and Mr Ehab Jirgis from the 
pET28b vector [60]. The vector contains a hygromycin resistance region (HYGR) for cell 
selectivity, a T7 promoter region for target protein expression, and a His-tag on both N-terminus 
and C-terminus (Figure 9). The difference in this construct is the replacement of the thrombin site 
with a TEV site. This was achieved through mutagenesis using In-Fusion HD Cloning Plus. In-
Fusion HD Cloning Plus is a product developed by Takara capable of cloning of any PCR fragment 
into any linearised vector in one 15-minute reaction. Techniques such as mutagenesis are also 
possible with the kit. The In-Fusion HD Cloning Plus kit provides a PCR premix and an enzyme 
premix which are used for this mutagenesis. Primers were designed with a 15 base pair overlap at 
the 5’ end, making the mutation of interest incorporated into the vector [61]. 
 
Figure 9: pYUB28b-TEV vector map highlighting features of interest (HYGR resistance region, His-tags, 
T7 promoter region, TEV cleavage site) Vector map created in SerialCloner. 
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2.2 Cell Lines Used in this Study 
2.2.1 Escherichia coli BL21 Expression Strain 
The E. coli BL21 DE3 strain was used to express Ec-MenD and Staphylococcus aureus MenD. 
This strain was generated from a previously prepared sample from the Dobson group by Dr Thu 
Ho. By using the E. coli cells for Ec-MenD, proper folding and the production of active protein 
has a higher chance of occurring. However, for Sau-MenD, S. aureus cells were not used for 
expression, increasing the risk for incorrect folding. 
2.2.2 Escherichia coli C41 Expression Strain 
The E. coli C41 strain was used to express Mycobacterium smegmatis MenD. This strain was 
generated from an imported agar plate by Dr Thu Ho. The E. coli cells being used for Smeg-MenD 
may not provide the proper folding for the protein nor the proper function of active protein which 
could become an issue in the results provided. 
2.2.3 Mycobacterium smegmatis mc24517 Expression Strain 
The M. smegmatis mc24517 was used to express Mycobacterium tuberculosis MenD. This strain 
was generated from M. smegmatis mc2155 by integrating a copy of T7 RNA polymerase which 
will induce the expression of recombinant protein by acetamide, lactose, or IPTG [62]. Much like 
using the E. coli cells for Ec-MenD, using closely related mycobacterial cells for production of 
mycobacterial proteins will provide the optimal opportunities for proper folding and functional 
protein production. 
2.3 Preparation of Expression Cells 
The chemically competent E. coli cells were prepared previously by Dr Jodie Johnston and Dr Thu 
Ho. These cells were grown using a SOB and TB medium system. The components of these are 
shown in Table 4.  
The electrocompetent M. smegmatis cells were also previously prepared by Dr Thu Ho and Dr 
Tamsyn Stanborough. These cells were grown using a 7H9/ADC/Tween-80 comprised medium 
as shown in Table 4. 
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Table 4: Components of various mediums 
SOB 250 ml TB 7H9/ADC/Tween-80 
20 g/L Tryptone 10 mM PIPES 4.7 g/L Middlebrook 
7H9 broth base 
5 g/L Yeast Extract 15 mM CaCl2 0.05% v/v Glycerol 
10 mM NaCl 250 mM KCl 10% v/v ADC 
98% Water and 
autoclave before next 
addition 
pH 6.7 using KOH 0.05% v/v Tween-80 
10 mM MgCl2 55 mM MnCl2  
10 mM MgSO4   
2.4 Transformation of Plasmids into Expression Cell Lines 
2.4.1 Antibiotics for Transformant Selection 
The antibiotic used for the E. coli BL21 expression system consists of ampicillin (50 µg/mL) or 
kanamycin (50 µg/mL). pET19 Ec-MenD has ampicillin resistance while BL21 has no antibiotic 
resistance, whereas the pET30a Sau-MenD has kanamycin resistance. These antibiotics will allow 
for selective growth so that all cells grown will have been transformed successfully. 
For the E. coli C41 expression system, the antibiotics used consist of hygromycin (50 µg/mL). 
pYUB28b-TEV-smegMenD has hygromycin resistance whereas the C41 strain has no antibiotic 
resistance. Again, this will ensure selective growth of transformed cells. 
2.4.2 Transformation into Escherichia coli BL21 and C41 cells 
The pET19 Ec-MenD or pET30a Sau-MenD constructs were transformed into the E. coli BL21 
cells for the expression of MenD. 1 µL of pET19 Ec-MenD or pET30a Sau-MenD construct were 
mixed with 50 µL of electrocompetent E. coli BL21 cells and incubated on ice for 15 minutes. The 
mixture was then heat shocked at 42 °C for 45 seconds, 500 µL of SOC medium was added and 
the mixture was incubated on ice again for 2 minutes. The mixture was then incubated at 37 °C 
for 1 hour and plated on LB agar containing 1 µL/mL ampicillin.  
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Similar to the pET19 or pET30a transformations, 1 µL of the pYUB28b-TEV-smegMenD 
construct was added to 50 µL of electrocompetent E. coli C41 cells and incubated on ice for 15 
minutes. This was then followed by heat shock for 45 seconds at 42 °C, addition of 500 µL of SOC 
medium and further incubation on ice for 2 minutes and then 37 °C incubation for 1 hour. This 
was then plated on LB agar containing 1 µL/mL hygromycin. These agar plates were then dried 
and sealed with parafilm and incubated at 37 °C for 1 day. 
2.5 Protein Expression 
2.5.1 Media for Auto-Induction Expression 
Auto-induction expression is a protein expression method which utilises the ability of lactose to 
induce production of a target protein without the need to monitor the growth or add inducer at a 
set time to ensure protein production. The technique identifies that lactose has the potential to 
cause automatic growth of BL21 cells if the compounds which prevent it from doing so are 
removed. There are three major factors that need to be considered when using an autoinduction 
system. These are; ensuring a source of carbon and energy being available, the importance of 
aeration for the level of target protein growth, and an inclusion of glucose into the auto-induction 
media at a reasonable concentration. This is done to ensure that cell growth to high density can be 
supported from the glucose presence, but also to ensure that lactose induction is not prevented 
from the glucose presence as lactose is the preferred metabolite for cells [63]. The media that was 
used in the auto-induction system for this work therefore had to cover all factors to ensure the most 
efficient growth. 
Tartoff-Hobbs (Terrific) Broth Medium is a nutritionally rich medium for bacteria growth that is 
recommended for the cultivation of E. coli recombinant strains. While in this medium, these strains 
have extended growth phases. The medium supports both high cellular density and mass as well 
as maintaining logarithmic growth for a long time, providing much higher yields of proteins and 
plasmid DNA. The media and purification process used utilises procedures established by previous 
work in this lab. The full list of ingredients used in this modified TB media are shown in Table 5  
[64]. This work utilises an auto-induction system which includes both Luria Broth and the TB 
media. 
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Colonies from the expression cells were taken and inoculated into ‘LB cultures’ of Luria Broth 
(LB) and the appropriate antibiotic for the plasmid. These LB cultures contained 30-50 mL of LB 
in Falcon Tubes. Depending on the cells growing, the LB cultures were then incubated at 37 °C 
for 1 day for E. coli and 3 days for M. smegmatis. Once expressed, these overnight cultures would 
then be used to inoculate the TB media for the next stage of the auto-induction system. 
All components of the Terrific Broth Media (TB Media) were sterilised by autoclaving at 121 °C 
for 15 minutes and filtered through a 0.2 µm filter. Any small filtration was done using sterilised 
plastic syringes using a 0.2 µm Minisart syringe filter while any larger volumes were instead 
filtered using a vacuum pump with the appropriate filtration apparatus and a Corning® 0.2 µm 
filter. All components of the TB media are shown in Table 5. The media used for the cultivation 
of E. coli were supplemented with polypropylene glycol 2000 (PPG) and the appropriate antibiotic 
for the plasmid present (ampicillin, kanamycin or hygromycin). PPG is used to prevent the build-
up of foam in the media during incubation without a negative effect on cell growth. For the M. 
smegmatis cells Tween-80 is supplemented instead of PPG. Large flasks were used to ensure 
proper aeration for growth, such as growing 500 mL culture in 1.5 L flasks and growing 1 L in 3 
L flasks. The amount of overnight culture used for each TB media was 10 mL/L. 3 L of culture 
were grown to ensure enough cell pellet will be present for purification as well as to ensure 
redundancy in case one was to fail to grow. The E. coli culture was incubated at 37 °C for 3-4 
hours before being left overnight in 18 °C with shaking, while the M. smegmatis culture is left at 
37 °C for 3 days while shaking. 
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Table 5: Contents of TB Media and the components involved 
TB Media Phosphate Mix (10x) 
Autoinduction 
Sugars 
12 g/L Tryptone 0.540 M K2HPO4 0.021 M Glucose 
24 g/L Yeast Extract 0.162 M KH2PO4 0.365 M Lactose 
0.8% Glycerol   
10% Phosphate Mix   




1.5% Aspartic Acid 
(25%) 
  
0.2% MgSO4   
1 Drop PPG   
Antibiotics   
 
2.5.2 Cell Harvest and Storage 
Cells were harvested from the flasks through centrifugation at 5000 g for 10 minutes at 4 °C. These 
were resuspended in a minimal amount of supernatant/MQ and aliquoted into 50 mL Falcon tubes 
for a further centrifugation step at 5000 g for 10 minutes at 4 °C. The supernatant was discarded, 
and the cell pellets were stored at -20 °C for future use. 
2.6 Protein Purification 
2.6.1 Protein Purification Buffers 
All buffers and solutions were filtered using a vacuum pump and a 0.2 µm filter and prepared with 
Milli-Q water. For the different cells, different buffers were used in some cases, these are shown 
in Tables 6-8. 
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Table 6: Purification buffer contents for Sau-MenD 




40 mM HEPES 
pH 8.0 
20 mM HEPES 
pH 8.0 
20 mM HEPES 
pH 8.0 
20 mM HEPES 
pH 8.0 
300 mM NaCl 150 mM NaCl 150 mM NaCl 150 mM NaCl 
10 mM MgCl2 5 mM MgCl2 5 mM MgCl2 5 mM MgCl2 
10% Glycerol 5% Glycerol 5% Glycerol 5% Glycerol 








Table 7: Purification buffer contents for Ec-MenD 




40 mM HEPES 
pH 8.0 
20 mM HEPES 
pH 8.0 
20 mM HEPES 
pH 8.0 
20 mM HEPES 
pH 8.0 
150 mM NaCl 75 mM NaCl 75 mM NaCl 75 mM NaCl 
10% Glycerol 5% Glycerol 5% Glycerol 5% Glycerol 










Table 8: Purification buffer contents for Smeg-MenD 




40 mM HEPES 
pH 8.0 
20 mM HEPES 
pH 8.0 
20 mM HEPES 
pH 8.0 
20 mM HEPES 
pH 8.0 
300 mM NaCl 150 mM NaCl 150 mM NaCl 150 mM NaCl 
10% Glycerol 5% Glycerol 5% Glycerol 5% Glycerol 









2.6.2 Protein Gel Electrophoresis 
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) is used to analyse the 
protein’s purity during the purification process. With the assistance of a protein molecular weight 
marker, the size of the protein sample can be estimated through observation of the band of a loaded 
sample. The SDS-PAGE gels were prepared in two different parts. Firstly, the resolving gel 
solution was prepared, which also included the use of isopropanol to remove any air bubbles found 
in the cast. This is left for an hour to set and is followed by the removal of the isopropanol and the 
addition of the stacking gel solution with a comb to form the wells for loading. The gel solutions 
components are shown in Table 9. The solution used for loading the wells with protein consisted 
of 4× loading buffer mixed with protein solution and incubated for 5 minutes at 98 °C to denature 
the protein. These samples are then loaded into the wells and the SDS-PAGE is mounted into a 
gel box filled with running buffer and run at 200 V and 30 mA for approximately 1 hour but until 
the dye has reached the bottom of the gel. The protein gel is then stained with Coomassie Blue 
stain solution overnight and destained with MQ. In each of the gel runs, protein molecular weight 
markers were loaded into the first well to measure protein size. 
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SDS Gel Loading 
Buffer 
12% Acrylamide 2.68% Acrylamide 62.5 mM Tris-HCl pH 
6.8 (Stacking Buffer) 
1% SDS 0.375% SDS 10% v/v Glycerol 
1% APS 1.6% APS 2% w/v SDS 
0.1% TEMED 1 drop 1% 
Bromophenol Blue 
100 mM DTT 
Resolving Buffer 0.13% TEMED 0.05% w/v 
MQ Stacking Buffer  
 MQ  
 
2.6.3 Cell Lysis 
Cell pellets were resuspended in 2× lysis buffer equal to the volume of cell pellet and were then 
lysed via cell disruption using the microfluidizer (M-110p) and 1× lysis buffer. Both the E. coli 
BL21 and C41 cells were passed through the microfluidizer to ensure complete lysis. To remove 
the proteins from cell debris centrifugation at 13000 rpm for 30 minutes at 4 °C. The supernatant 
is collected and chilled on ice for purification step. 
2.6.4 Immobilised Metal Affinity Chromatography (IMAC) 
IMAC is a purification technique that uses packed resins inside a column with immobilised metal 
ions present to bind specifically to residues with high affinity to metal ions. These ions are 
generally Ni2+ or Co2+ and are consistently found binding to His tags. In the case of all three 
purification in this work, a column with Ni2+ was used. The supernatant which contained the 
protein was filtered first with a sterile 0.8 µm syringe filter followed by a 0.5 µm syringe filter 
then loaded onto the column using an AKTA system pump which had a 0.8 µm and 0.5 µm 
connected to the column in the AKTA path. The loading of the protein was then washed using 1× 
lysis buffer.  
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Once loaded, the AKTA then ran a gradient wash through the column which used the elution buffer 
containing high imidazole content. The gradient progressed from 50 mM to 500 mM imidazole 
while fractions of 5 mL were collected. The fractions were analysed using SDS-PAGE to identify 
fractions containing protein. These fractions were pooled together according to the observations 
from the gel and prepared for the next step in the purification process. For the pYUB28b-TEV-
smeg-MenD protein, an additional step was taken to remove the histidine tag. 
2.6.5 rTEV digestion 
The pYUB-TEV-smegMenD protein as mentioned previously contains a histidine tag incorporated 
which ultimately must be removed to observe intended interactions of the proteins during 
experimental testing. Using recombinant Tobacco etch virus protease (rTEV protease), this 
histidine tag can be cleaved from the purified protein. The protease was created during previous 
work and provided for this study. A buffer identical to the size exclusion buffer used for pYUB28b-
TEV-smegMenD was used to soak the dialysis membrane tubing which had a molecular weight 
cut off of 10 kDa used in this digestion. 
500 µL of 1.3 mg/mL rTEV protease was mixed with 50 mL of the protein fractions and dialysed 
at 25 °C overnight. Cleavage was checked with SDS-PAGE which did not display clear cleavage. 
Another IMAC purification step was then used on the protein and the rTEV cleavage was 
reattempted. 1 mL of rTEV protease was mixed with 30 mL of the protein fractions and dialysed 
at 37 °C for 5 hours and at 4 °C for a further 2 days. Determination of cleavage from this was 
achieved using SDS-PAGE. 
2.6.6 Size Exclusion Chromatography (SEC) 
Size exclusion chromatography is a purification technique that allows proteins to be purified based 
upon size. Beads with various sized pores are found in the column allowing proteins to pass 
through. These beads separate proteins based on their size and this size also determines how long 
elution takes. Large proteins will elute quickly as they do not pass through any of the pores in the 
column, while the smallest proteins will pass through every pore, resulting in a much longer time 
before elution. All proteins present will range between these two situations and therefore knowing 
the size of the protein will help determine how long it will take to elute. 
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Before loading onto the SEC column, the protein fractions were first concentrated using a 
centrifugal filter (cut off molecular weight 10 kDa) by centrifuging at 5000 rpm at 4 °C. Once the 
protein was concentrated to an acceptable volume it was again filtered using a 0.2 µm syringe 
filter.  
The SEC purification step used a Superdex 200 (10/300 GL) column on an AKTA system at room 
temperature. Before purification, the column was washed through with two column volumes of 
MQ followed by equilibration using the prepared SEC buffer. The concentrated protein was loaded 
into the system using a 0.2 µm syringe filter and then injected into the system. The eluted protein 
fractions were then collected in 1 mL volumes. The fractions showing any potential protein were 
analysed using SDS-PAGE. 
2.7 Protein Concentration and Storage 
The fractions which displayed a single band from the SDS-PAGE were pooled together and further 
concentrated to around 10 mg/mL. The actual concentration of the protein was recorded, and the 
protein was then snap frozen in liquid nitrogen in 100 µL units and stored at -80 °C. 
The protein was concentrated using centrifugal filter concentrators of either 15 mL or 2 mL max 
volume with a molecular cut off of 10 kDa. These were centrifuged at 4000 rpm at 4 °C. To 
quantify the protein was successfully concentrating/at an acceptable concentration a NanoDrop 
1000 Spectrophotometer was utilised. By receiving the absorbance of the sample at 280 nm and 
having knowledge of the proteins molecular weight and extinction coefficient the concentration of 
the protein could be determined using Beer’s Law, 
     c = A/εl 
where c is protein concentration, A is absorbance at 280 nm, ε is the molar extinction coefficient 
and l is the path length of sample. 
2.8 Compounds Used During Experiments 
In this work several different compounds were used which were all purchased from available 
sources (Sigma-Aldrich). These compounds have been identified as positive hits for potential 




2.9 Differential Scanning Fluorimetry (DSF) 
Differential Scanning Fluorimetry (DSF) is an assay technique that is used to assess the stability 
of a protein in the presence of various potential binding ligands at various temperatures. The DSF 
experiments were set up with 25 µL reaction volumes of each condition in PCR 96-wells plates. 
The contents of each reaction are shown in Table 10. The plates were cleared of air bubbles, sealed 
to prevent evaporation during the experiment and then placed in the PCR machine where the 
protocol was run. The run was a melt protocol which evolved from 20 °C to 95 °C at 1 °C per 
minute.  
The protein structure will denature as the temperature of the PCR machine increases. As this 
happens, the SYPRO orange dye in the reaction can then bind to more exposed hydrophobic 
regions and emit fluorescence. This fluorescence is then picked up by the PCR machine and 
recorded. The change of this fluorescence over the increasing temperature of the PCR machine 
produces a melting curve for each reaction on the plate. The raw data from this experiment is then 
analysed using the Protein Thermal ShiftTM software. Every thermal melt curve and melting 
temperature (Tm) is compared to appropriate controls to identify potential interactions between the 
protein and a ligand. For each protein used, the ligands used in each set of experiments were the 
same. However, the contents of the reaction were appropriate to the protein used (shown in Table 
10). Five plates were created for each protein used in this work, all with the same format except 
for the ligands added. An increase in Tm suggests that the compound interacts with and stablilises 
the protein while decreases in Tm suggest the opposite with destabilisation of the protein. Any 
deviation of the Tm greater than 0.5 °C (positive or negative) after all corrections using the 
appropriate controls have been made will be considered to suggest an interaction and will be 
included in discussion. 
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Table 10: DSF buffer contents for the three proteins used in this work 
DSF Reaction for 
Sau-MenD 
DSF Reaction for 
Ec-MenD 
DSF Reaction for 
Smeg-MenD 
5 µM Sau-MenD 5 µM Ec-MenD 5 µM Smeg-MenD 
20 µM HEPES pH 8.0 20 µM HEPES pH 8.0 20 µM HEPES pH 8.0 
150 µM NaCl 75 µM NaCl 150 µM NaCl 
1 mM MgCl2 1 mM MgCl2 1 mM MgCl2 










2.10 Intrinsic Fluorescence Quenching (IFQ) 
Intrinsic protein fluorescence is an effective tool used to study both protein conformation and 
protein-ligand interactions. The technique specifically looks at the most predominant fluorescent 
amino acid tryptophan, which absorbs at a wavelength of 280 nm and emits in a range from 300-
350 nm depending on environment polarity [65]. The fluorescence of tryptophan is capable of 
being strongly influenced by residues/compounds found adjacent to the tryptophan, which makes 
it an effective detection strategy for binding occurring near the residue. In addition to this, the 
overall rarity of tryptophan in protein structure adds to the ability to measure conformational 
changes based upon the observed fluorescence and quenching. IFQ was used in favour of other 
fluorescence techniques due to the ability to detect the fluorescence without the need to covalently 
modify the molecule which could result in further unintended conformational or other changes. 
The IFQ experiment was conducted using an assay buffer shown in Table 11. This buffer was 
added to quartz cuvettes with 10 mm path length. 1-2 µM concentration of protein was added to 
these cuvettes as well as any additional ligands added. These additional ligands used were DHNA, 
ThDP, TCEP and oxoglutarate which could be added in various ways. The setup of these 
experiments is shown in Table 11. 45-minute incubation stages were required for certain 
experiments which involved compound and protein interactions. These compounds were not the 
main focus of the experiment instead being an additive necessary for the appropriate reaction to 
be observed. The ligand DHNA had to be prepared through addition to DMSO solution. This also 
required an incubation time of 45 minutes, which when possible was prepared alongside any other 
incubation stages. 
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The experiment utilised a Cary Eclipse Fluorescence Spectrophotometer where the reactions were 
run at an excitation wavelength of 290 nm and measured an emission at 340 nm. Fluorescence 
excitation at 290 nm and not 280 nm was done to ensure the tryptophan emission spectrum would 
be dominant over other amino acid fluorescence from tyrosine and phenylalanine. Two readings 
were made as a ligand was titrated into the cuvette at increasing volume (and concentration) over 
time. The A290 and emission reading at 340 nm were recorded and analysed using the analysis 
package designed by Allison et al. Fluorescence intensity versus ligand concentration were plotted 
and fitted to determine the Kd.  
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Fluorescence quenching arises from several different mechanisms which can be collected under 
two main classifications. These are dynamic quenching (collisional encounters between 
fluorophores and quenchers) and static quenching (ground-state complex formation between 
fluorophores and quenchers) [66]. Dynamic quenching includes proton and electron transfer and 
long range energy transfer, which involve the excited fluorophore colliding with ions and returning 
to ground state in non-radiative manners, whereas static quenching such as conformational 
changes and intramolecular interactions occur when the fluorophore and quencher form a ground 
state complex which prevents excitation of molecules [67]. 
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2.11 Inner Filter Effect 
The absorbance or optical dispersion of light at the excitation of emission wavelength by a 
compound in the fluorescence assay is known as the inner filter effect (IFE). This can affect 
fluorescence experiments in a negative way, providing false positives or misinformation shown as 
non-linearity of fluorescence intensity and fluorophore connection [68]. While one option is to 
ignore the IFE if absorbances are negligible [69], in the case of this work an attempt to estimate 
the inner filter effect and correct for it has instead been done using the following equation.  




Where Fi corr is the corrected value of fluorescence intensity at the titration point, Fi dil is the dilution 
corrected fluorescence intensity measured, Aex is the absorbance of sample at excitation 
wavelength and Aem is the absorbance of sample at emission maximum [68]. 
By first determining the absorbance of ligands being added to the cuvette, these absorbances can 
be used in the equation to account for the ligand presence and provide a more accurate 




Chapter 3. Protein Purification  
3.1 Origin and Purification of Proteins  






Source of cells from 
expression work 
Purification steps 
done in this work 






Cleaved from Protein 
via rTEV 
Obtained purified 
protein from Dr 
Stanborough 
No purification steps 
done. 
Purified protein 
obtained from Dr 
Stanborough 
Mtb-MenD pYUB28b-TEV N-terminal histidine 
tag. 




protein from Dr Ho 
No purification steps 
done. 
Purified protein 
obtained from Dr Ho 
Ec-MenD pET19 N-terminal histidine 
tag. 




Smeg-MenD pYUB28b-TEV N-terminal histidine 
tag. 
TEV cleavage site 
replacing thrombin 
cleavage 
Obtained cells from 








In this work Ec-MenD was purified using the methods described in Chapter 2; briefly the pellets 
containing over-expressed MenD were lysed using a cell disruptor then purified via immobilised 
metal affinity chromatography (IMAC) and size exclusion chromatography (SEC). The N-terminal 
hexa-histidine tag was linked to MenD via short sequence containing a thrombin cleavage site and 
was not cleaved.  
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3.2.1 Ec-MenD IMAC  
IMAC purification of Ec-MenD successfully separated the desired protein from the protein mix 
found in the cell pellet. As shown in Figure 10, purification of Ec-MenD was highly specific, with 
only one major elution peak (fractions 6-8) observed during the IMAC purification process. 
 
Figure 10: Ec-MenD IMAC chromatogram. Blue line is the UV absorbance at 280 nm with one major 




Figure 11: SDS-PAGE showing progression from before and including IMAC purification. From left to 
right the lanes are: protein standard, cell pellet and lysis buffer, cell pellet after cell disruptor, supernatant 
after centrifugation, cell pellet after centrifugation, protein flow through, fraction 4, fraction 6, fraction 7, 
fraction 8. 
 
3.2.2 Ec-MenD SEC  
Based on the results from the SDS-PAGE, fractions 6-8 were pooled and concentrated for further 
purification by size exclusion chromatography on a S200 16/600 column. This column contains a 
void volume of  20 mL. Void volume is a reference to the liquid phase volume that is contained 
inside a column. The void volume of a column varies depending on the size of the column as well 
as the volume of support moleules found inside the column. The protein was purifed in one run, 
and demonstrated a single large peak starting at approximately 35 mL after protein injection. All 
fractions in this peak (B3 – C5) were considered important in terms of protein presence, however 




Figure 12: Ec-MenD SEC chromatogram. Blue line shows UV absorbance at 280 nm. One major broad 
peak observed between 30-60 mL. 
Figure 13: SDS-PAGE demonstrating progression of SEC purification. From left to right: Protein 
standard, fraction B7, B8, B9, B10, B11, B12, C1, C2, C3. Fractions B9-B12 appear to have a second 
smaller band below the protein. 
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3.3 Smeg-MenD 
The N-terminal hexa-histidine tag on the Smeg-MenD protein was removed using rTEV (rTEV 
site which was incorporated into the Smeg-MenD protein was utilised) and hence this protein 
purification required additional steps compared to Ec-MenD. This is detailed in chapter 2 (sections 
2.5, 2.6). 
3.3.1 IMAC Step 1 
IMAC purification successfully separated Smeg-MenD in the cell pellet from the protein mix 
found. Figure 14 demonstrates a progressive protein separation throughout the purification process 
with the majority of Smeg-MenD found at fractions 4-7.  
 
Figure 14: IMAC of Smeg-MenD chromatogram. The blue line highlights the UV readings of the protein 
with higher UV recordings likely correlating to protein presence. 
44 
 
Figure 15: SDS-PAGE including both progression from before and including IMAC purification. From 
left to right these are; Standard/gel ladder, blank space, Cell pellet after centrifugation, flow through from 
IMAC, fraction 3, 4, 5, 6, 7, 8. 
 
3.3.2 Cleavage with rTEV and Reverse IMAC 
Fractions with positive confirmation of purified protein were pooled for dialysis (50 mL). These 
fractions were placed in dialysis tubing and set in a non-imidazole containing buffer for dialysis. 
Prior to dialysis, 500 µL of rTEV protein was added to the protein fractions to remove the histidine 
tag (as mentioned in chapter 2).  The dialysis setup was placed at 25 ˚C overnight. 
SDS-PAGE analysis of the initial cleavage suggested that the tag had not completely cut (Figure 
16). A reverse IMAC was undertaken to check for any completely cleaved protein. A broad region 
of low absorbance was observed in the flowthrough followed by two more standard peaks 
(fractions 4-5 and then 6-7). The fractions were analysed on an SDS-PAGE gel, which suggested 
only one band was present. As these had stuck to the IMAC column it was considered likely they 
still retained their tag. At the time of this work the flowthrough observation was not thought to 
contain protein and so was not used in further purification however after further purification work 
it has been noted that this was likely a significant amount of cut protein.  
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Figure 16: SDS-PAGE from first Smeg-MenD dialysis (His-tag cleavage) experiment. From left to right; 
protein standard, protein before dialysis, protein after dialysis. The small yet distinct band at the bottom 
of this well is likely the rTEV protein presence.  
 
Figure 17: Smeg-MenD reverse IMAC chromatogram. Unlike the first IMAC experiment the UV peaks 
are more specific and cover a smaller range of volume, implying higher specificity in the protein than 
previous. 
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Figure 18: Gel run focusing on the fractions from the reverse Smeg-MenD IMAC experiment. From left 
to right; protein standard, space, fraction 4, 5, 6, 7.   
Fractions 4-5 were pooled as were 6-7 and a higher concentration of rTEV (1 mL of 500 µM for 
30 mL) was added. The two pooled proteins were dialysed at 37˚C for 5 hours followed by 4˚C 
for 3 days.  A gel was run again to confirm if successful cleavage had occurred in either case. 
However, the amount of protein used to check appeared to be overloading the wells and made it 
difficult to determine the presence of two different bands. A second gel run with less protein 
present in the wells was also completed and this distinctly displayed successful cleavage of the 




Figure 19: SDS-PAGE from the second Smeg-MenD dialysis (His-tag cleavage) experiment. From left to 
right, fractions 4-5 before cleavage, fractions 4-5 after cleavage, fractions 6-7 before cleavage, fractions 
6-7 after cleavage, protein standard. Both fractions before cleavage display a band at a much lower 
molecular weight, which is likely to correspond to rTEV.  
 
Figure 20: Second SDS-PAGE for second Smeg-MenD dialysis with reduced protein volume for better 
identification of the two protein bands. The only relevant bands for this gel run are the 4th, 5th, and 6th 
from the right as these are pooled fractions 4-5 after cleavage, pooled fractions 6-7 after cleavage and 
fraction 4-5 before cleavage. 
48 
3.3.3 Smeg-MenD SEC 
The protein from the second rTEV cleavage attempt was not further purified by reverse IMAC. 
Instead the protein was purified by size exclusion chromatography using S200 10/30. Protein was 
concentrated and purified in three runs. As seen in Figure 21, each protein load provided an 
identical purification reading, with peaks of interest at 1-2 and 4-6 for A, B and C. Of the most 
interest were the peaks at 4-6 as the protein was expected to take 10-12 mL of buffer run through 
the column before the protein would then come off. Any peaks observed before 10-12 mL of buffer 
were considered void volume. This void volume generally contains any aggregated protein. Above 
this volume it is less likely that any peaks are of aggregated protein because this is consistent with 
the observed tetramer elution found with Mtb-MenD purification These were then loaded onto a 
SDS-PAGE gel for further confirmation of protein presence. All three runs of the SEC column 
demonstrated similar results as seen on the gel in Figure 22.  
 
Figure 21: Smeg-MenD SEC purification chromatogram. The blue line represents the UV absorbance 
readings at 280 nm and the red line represents UV absorbance readings at 254 nm. The overall trends are 
seen repeated between all three runs. 
  
49 
Figure 22: SDS PAGE after successful SEC purification. From left to right: Protein standard, Fraction 
A2, A4, A5, B2, B4, B5, C2. C4, C5. Each well shows additional bands below the protein, with the 




Chapter 4. Intrinsic Fluorescence Quenching 
Measurements of Ligand and Substrate Binding to 
MenD from S. aureus, E. coli, and M. smegmatis 
4.1 Introduction 
4.1.1 Background and Overall Goals 
The main goal of the work presented in this chapter was to determine the binding affinity of various 
MenD substrates and ligands. This goal had two primary aims: 
• The determination of whether DHNA binds, and binds with a similar affinity, in MenD 
enzymes from three different species as it does to Mtb-MenD. If DHNA does bind 
equivalently between these MenD enzymes this suggests that inhibitors that bind 
preferentially over DHNA will do so in all enzymes, and consequentially would bind 
equally to all disease-relevant MenD enzymes, such as Mtb-MenD. 
• An investigation into the binding of ThDP, and 2-oxoglutarate. ThDP and 2-oxoglutarate 
are the co-factor and substrate of MenD, respectively, so determining and comparing the 
binding strength of these compounds between MenD enzymes from different species is 
beneficial information for drug design.  
The three compounds used in these experiments were DHNA, ThDP, and 2-oxoglutarate. ThDP, 
or thiamine diphosphate is the co-factor essential to the ability of the enzyme to decarboxylate 2-
oxo acids. ThDP binds in the active site in a divalent metal-ion dependent manner. 
2-Oxoglutarate is the ligand responsible for the formation of SEPHCHC by MenD. When bound 
to ThDP, 2-oxoglutarate undergoes a decarboxylation reaction which then prepares the ligand to 
interact with isochorismate, with which it will then form a new carbon-carbon bond. Like ThDP, 
2-oxolgutarate binds to the active site of MenD. 
By contrast, DHNA does not bind to the active site of MenD, instead binding to an allosteric site. 
DHNA is the product of MenI, an enzyme further along in the menaquinone biosynthesis pathway, 
and is a negative feedback regulator for the biosynthetic cycle in M. tuberculosis. 
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4.1.2 Intrinsic Fluorescence Quenching for Measuring Binding 
Interactions 
A range of different methods are available to detect small molecule binding to proteins. These 
methods include but are not limited to: surface-plasmon resonance, isothermal titration 
calorimetry, differential scanning fluorimetry, and mass spectrometry. Each technique provides its 
own unique strengths and weaknesses in this characterisation process, which can often depend on 
the system under study and the binding parameters which are capable of being measured. 
One method to detect small molecule binding to proteins is the use of intrinsic fluorescence 
quenching assays (IFQ). These assays use naturally occurring tryptophan residues present in the 
proteins in question to investigate the binding of any ligand that could cause changes in the 
fluorescent properties of these tryptophan residues. By measuring fluorescence as a function of 
ligand concentration, binding curves can be generated that show proportional changes in 
fluorescence correlated to ligand binding in a protein. These binding curves can be fitted with 
equations for binding to derive dissociation constants that describe the strength of binding 
interaction. 
Several research groups have previously used this method for characterising the binding of ThDP 
to ThDP-dependent enzymes [68, 70]. Assuming that any ligand binding (including ThDP) to 
either the active site of MenD or an allosteric site will result in a change of fluorescence, IFQ can 
be a useful technique for measuring binding affinities for MenD ligands. A major advantage of 
using IFQ is the relatively small amount of protein consumed in experimental work, as well as the 
technique being label-free, producing results with less potential for interference or artefacts. 
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4.1.3 Prior IFQ-based Studies of Mtb-MenD  
Previously completed work in this field has established the Mtb-MenD allosteric site [41]. This 
site contains several key conserved residues, namely Tyr95, Arg97, Arg277, Arg303 and Trp304. 
These residues are key to binding the inhibitor DHNA, with the residue of highest interest for this 
work being the Trp304 [41]. The main structure of the allosteric site of Mtb-MenD is an arginine 
‘cage’ made up of Arg97, Arg277 and Arg303 (Figure 23) [41]. These three arginine residues 
surround DHNA in its binding site and all interact directly with DHNA. In addition, these arginine 
residues are potential candidates for signalling between the allosteric and active site of Mtb-MenD. 
The residue Trp304 is of particular interest in relation to IFQ experiments due to the high level of 
intrinsic fluorescence this amino acid contains and the proximity of this particular tryptophan 
residue to the allosteric site. Any changes observed in the intrinsic fluorescence of the enzyme are 
likely going to contribute at least in part to an effect upon this residue specifically. 
 
Figure 23: Allosteric site from Mtb-MenD with the conserved and important residues labelled. Three 
arginine residues make up the cage (Arg97, Arg277, Arg303) while the most fluorescently important 
(Trp304) is near the allosteric site. Image adapted from[41]. 
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In previous IFQ work on Mtb-MenD conducted by Dr Thu Ho and Dr Tamsyn Stanborough, ThDP 
binding was not able to be measured due to binding not causing any change in fluorescence after 
inner filter effect corrections were applied. However, this technique was discovered to be suitable 
for measuring DHNA binding and could prove to be useful for 2-oxoglutarate as well. 
4.1.4 Active and Allosteric Sites of Ec-MenD, Sau-MenD and Smeg-
MenD 
The sequence alignment shown in Appendix 1 demonstrates a large degree of conserved residues 
in all four MenD species, in particular those residues also located in the active site for Mtb-MenD. 
The key residue Glu55 is found to be conserved, alongside both an Asp and Arg residue before 
and after respectively. Similarly, the His445 residue is also found to be conserved in three of the 
four MenD enzymes, with Ec-MenD replacing this with a Tyr instead. All four enzymes however 
have a conserved Asp residue directly following this residue, suggesting some degree of 
conservation present. The remaining two key residues found in the active site, Ile404 and Ala402 
are found conserved in all proteins for Ile, and only in Smeg-MenD and Mtb-MenD for Ala402. 
The residues which make up the allosteric site for Mtb-MenD have been determined, but these 
don’t appear highly conserved across all MenD enzymes from other species, and in general domain 
II, where the allosteric site resides, is the least conserved of the domains. Experimental work such 
as IFQ which manipulates the intrinsic fluorescence of residues such as Trp can provide 
information on if MenD enzymes from other species can bind to the allosteric effector DHNA 
despite the lack of conservation. This can be determined based upon the amount of fluorescence 
present in the protein and how large of an effect the binding of DHNA has on this signal. Table 13 
shows the number of Trp residues present in each of the MenD enzymes, with a secondary count 
of which of these Trp residues are not conserved between at least three of the proteins. It is 
immediately clear that Ec-MenD is expected to exhibit the most fluorescence activity of all the 
proteins, with 17 Trp residues present. The remaining three proteins have only four Trp residues, 
with Mtb-MenD and Smeg-MenD observed to have identical Trp residue locations. There is only 
one Trp residue that is conserved between all four proteins, Trp 328. This is neither in the allosteric 
site nor the active site but is not too far from the 299-310 region that contributes to the allosteric 
site. The Trp304 in the allosteric site of Mtb-MenD is not conserved in any other protein but Smeg-
MenD. In addition, because the proteins are known to be conformationally flexible when binding 
to their co-factor and substrates even in the absence of a Trp directly in the active site there is a 
possibility that there will be quenching detectable from even remote Trp’s on ligand binding. 
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Table 13: Count of tryptophan (Trp) residues present in each MenD protein. 




Mtb-MenD 4 1 
Smeg-MenD 4 1 
Ec-MenD 17 13 
Sau-MenD 4 2 
 
4.2 IFQ Experiments with Sau-MenD  
For all IFQ experiments no replicates were completed due to time constraints. This limits the 
interpretation of the results as they are yet to be replicated. Future work requires these IFQ 
experiments to be replicated for any publications to be made from this work. 
4.2.1 ThDP 
The magnitude of quenching intensity observed in the ThDP binding experiments with Sau-MenD 
was modest, yet the signal was sufficient to show clear binding (Figure 24) with an estimated Kd 
in the micromolar range both in the presence and absence of 2.5 mM TCEP (Table 14). The 
presence of TCEP appeared to increase the Kd but also changed the shape of the curve which fitted 
better to the bimodal equation implemented in the Allison et al IFQ analysis package used to create 
the graphs. Both results are within the micromolar range and the absence of replicates leads us to 
be unable to draw conclusions on any significance in the differences with TCEP added. 
Table 14: Kd values of Sau-MenD under various ThDP conditions 
 Kd with MgCl2 
added 
(µM) 




ThDP 47.0 0.4 - - 
ThDP with TCEP 
Present 





Figure 24: Top (a): ThDP binding to Sau-MenD with MgCl2 present. Bottom (b): ThDP binding to Sau-
MenD with MgCl2 and TCEP present. 
  
ThDP Binding to Sau-MenD 
ThDP Binding to Sau-MenD with TCEP Present 
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4.2.2 2-Oxoglutarate  
This ligand is a substrate of MenD and will react, so the Kd calculated could be from binding or 
changes during reaction or a combination thereof. It therefore is not technically a Kd, but a measure 
of interaction nonetheless. Due to time constraints this complexity was not explored further in this 
thesis and for simplicity we have termed it Kd in the following discussion. Experiments involving 
2-oxoglutarate addition included 100 µM ThDP in the protein buffer mix and were incubated for 
an hour to ensure full interaction between protein and ThDP occurred. The experiment involving 
2-oxoglutarate and ThDP did not provide useable results from this work and so has been omitted. 
The 2-oxoglutarate binding in the presence of ThDP and TCEP Kd is estimated to be in the low 
micromolar region (5.4 µM, Table 15). This suggests tighter binding of 2-oxoglutarate than ThDP 
with a 10-16-fold lower Kd than that measured for ThDP. However, the 2-oxoglutarate experiments 
show lower quenching signal and more noise (reflected in the lack of data for TCEP free 
experiments) so the significance of this would need to be confirmed by replicate experiments. Due 
to the absence of the experiment without no TCEP, it is difficult to determine what effects TCEP 
may have on the measured Kd and magnitude of binding of 2-oxoglutarate. 
 
Figure 25: 2-Oxoglutarate binding to Sau-MenD with MgCl2, ThDP and TCEP present. 
  
2-Oxoglutarate Binding to Sau-MenD with ThDP and TCEP Present 
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Table 15: Kd values of Sau-MenD with MgCl2, ThDP and TCEP present. 




2-Oxoglutarate with ThDP and TCEP Present 5.4 0.4 
 
4.2.3 DHNA 
The majority of the IFQ experiments for all proteins used DHNA, as this inhibitor was of the most 
interest. Initial experiments looked at the quenching of DHNA in buffer with and without the 
presence of TCEP. As mentioned before the use of TCEP was due to its strong reducing potential 
and the ability of DHNA to oxidise during the experiment in its absence. DHNA is also unique 
compared to the previous ligands as it is an allosteric inhibitor rather than being found at the active 
site. 
Binding of DHNA to the protein in the presence and absence of 2.5 mM TCEP produced almost 
identical results (Figure 26 a and b) with a Kd of ≈1 µM (Table 16) suggesting tight binding and 
supporting the idea that this allosteric regulator does bind and could have a similar allosteric 
inhibition as observed in Mtb-MenD. 
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Experiments involving DHNA binding with 100 µM ThDP present in the buffer suggests a lower 
binding affinity for DHNA with an estimated Kd about 50-fold less (of 57 µM, Figure 26c, Table 
16) compared to solely DHNA binding. When ThDP and TCEP is present the curve fitting that 
appears to fit best is bimodal, suggesting a higher and lower affinity DHNA binding site may be 
present. The higher binding site being tighter than that seen in the apo protein DHNA binding 
experiments (1 µM versus <0.03 µM, Figure 26d, Table 16) while the second site is lower (171.3 
versus 1 µM, Table 16, Figure 26d). This is an interesting finding which may suggest an interaction 
or a conformational change of Sau-MenD when ThDP is bound which interferes or affects DHNA 
binding, and hints that this could affect the symmetry of the four potential DHNA binding sites in 
the tetramer. The significance of the differences between the experiments with and without TCEP 
is unclear, however TCEP keeps DHNA reduced so the clearer results with TCEP present may 
reflect the ability of TCEP to keep DHNA in an oxidation state that is preferred for binding. It may 
also be the bimodal nature of the ThDP without TCEP binding curves was missed in this analysis 
(which would affect the Kd estimated here) and indeed close inspection of the graphs suggests this 
may be bimodal as well. Experiments measuring the binding of DHNA to protein where both 100 
µM ThDP and 2-oxoglutarate were present, show similar binding Kd estimates to the apo protein, 
while with TCEP fitted best to the bimodal curve fitting with a tight and weaker binding affinity 
site. These experiments were not done in replicate so any firm conclusion is pre-emptive, 
nonetheless these findings confirm DHNA binds consistently to the protein in many different 
catalytic states and may show differences when co-factor is bound. This preliminary finding is 




DHNA Binding to Sau-MenD 




DHNA Binding to Sau-MenD in the presence of TCEP 
DHNA Binding to Sau-MenD in the presence of ThDP and TCEP 
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Figure 26: DHNA binding to Sau-MenD under various conditions. 1st Row (a): MgCl2 present. 2nd Row 
(b): MgCl2 and TCEP present. 3rd Row(c): MgCl2 and ThDP present. 4th Row(d): MgCl2, ThDP and 
TCEP present. 5th Row(e): MgCl2, ThDP and 2-oxoglutarate present. 6th Row(f): MgCl2, ThDP, 2-
oxoglutarate and TCEP present.  
DHNA Binding to Sau-MenD in the presence of ThDP and 2-Oxoglutarate 
DHNA Binding to Sau-MenD in the presence of ThDP, 2-Oxoglutarate and TCEP 
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Table 16: Kd values of Sau-MenD under various DHNA binding conditions 
 Kd With MgCl2 
Added 
(µM) 




DHNA 1.2 0.04 - - 
DHNA with TCEP 
Present 
1.9 0.04 - - 
DHNA with ThDP 
Present 
52.3 0.8 - - 
DHNA with ThDP and 
TCEP Present 
0.003 0.000 171 3 
DHNA with ThDP and 
2-Oxoglutarate Present 
1.90 0.02 - - 
DHNA with ThDP, 2-
Oxoglutarate and 
TCEP present 
0.01 0.00 88 2 
 
4.3 IFQ Experiments with Ec-MenD 
4.3.1 ThDP Binding 
The binding of ThDP to Ec-MenD appears to fit the bimodal equation for curve fitting favourably. 
This suggests that there is a higher and lower affinity ThDP binding site for Ec-MenD, with a 
significant difference observed between these sites (Kd of 0.003 µM in tight binding site versus 
119 µM, Table 17). These results are found in the nanomolar range and the micromolar range 
respectively, however there is enough of a difference to consider this a significant observation. 
The presence of TCEP both changed the shape of the curve as it no longer fit best to the bimodal 
equation and increased the Kd (Table 17). Clear binding of ThDP to Ec-MenD was observed in 
both experiments (Figure 27), however due to the absence of replicates no further conclusions 
about the effect of TCEP to the binding of ThDP can be made. 
Table 17: Kd values of Ec-MenD under various ThDP conditions. 








ThDP 0.003 0.001 119 4 
ThDP with TCEP 
Present 




Figure 27:  ThDP binding to Ec-MenD under various conditions Top (a): MgCl2 present. Bottom (b): 
TCEP and MgCl2 present. 
  
ThDP Binding to Ec-MenD with MgCl2 addition 
ThDP Binding to Ec-MenD in the presence of TCEP with MgCl2 addition 
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4.3.2 2-Oxoglutarate Binding 
Experiments involving 2-oxoglutarate addition included 100 µM ThDP in the protein buffer mix 
and were incubated for an hour to ensure full interaction between protein and ThDP occurred. 
Binding of 2-oxoglutarate in the presence and absence of TCEP provided nearly identical results 
(Figure 28), each with incredibly steep decreases in fluorescence over a very minor 2-oxoglutarate 
concentration increase suggesting tight binding of 2-oxoglutarate to Ec-MenD in the presence of 
ThDP. Only upon further inspection of the respective Kd for these experiments can it be seen that 
in the absence of TCEP 2-oxoglutarate binds slightly tighter to Ec-MenD (Table 18) but this is in 
likely experimental variation given the lack of replicate experiments. In TCEP presence the Kd of 
2-oxoglutarate is observed to be 20-fold lower than the previous ThDP binding experiment (1.68 
versus 34.78 µM, Figure 28b, Table 17), however due to the difference in curve fitting equations 
between non-TCEP addition experiments for ThDP and 2-oxoglutarate no direct comparisons can 
be made between these results (Figure 27a, Table 16). 
Table 18: Kd values of Ec-MenD under various 2-oxoglutarate conditions 
 













Figure 28: 2-Oxoglutarate binding to Ec-MenD under various conditions. Top (a): ThDP and MgCl2 
present. Bottom (b): ThDP, TCEP and MgCl2 present. 
  
2-Oxoglutarate Binding to Ec-MenD in the presence of ThDP with MgCl2 addition 
2-Oxoglutarate Binding to Ec-MenD in the presence of ThDP and TCEP with MgCl2 addition 
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4.3.3 DHNA Binding 
Experiments involving DHNA addition in the presence and absence of 2.5 mM TCEP support 
binding of DHNA to Ec-MenD (Figure 29 a and b). The DHNA to apo Ec-MenD protein and 
DHNA to Ec-MenD protein in the presence of ThDP and 2-oxoglutarate (with and without TCEP) 
fitted best to the single binding model. While DHNA binding to apo Ec-MenD where TCEP was 
present and to Ec-MenD with ThDP present (with or without TCEP) appeared to fit best to a 
bimodal model suggesting potentially in these cases a higher and lower affinity binding site for 
DHNA and by extension suggests an effect upon the symmetry upon the potential binding sites of 
DHNA. Further replicates need to be done to ensure that bimodal binding has not been missed for 
the other experiments and is not an over interpretation. Examination of the results suggests that 
the binding of DHNA is the weakest in the apo Ec-MenD protein with no co-factor (ThDP), 
substrate (2-oxoglutarate) or reducing agent (TCEP) present (Table 19, Figure 29a). It is harder to 
directly compare dissociation constants between bimodal and single curve fitting experiments but 
it appears that binding in the presence of co-factor or reducing agent results in significantly tighter 
binding if the assumption that there are two binding sites with different affinity in the enzyme is 
correct (Table 19, Figure 29c, d). If you compare apo Ec-MenD with TCEP versus Ec-MenD with 
ThDP and TCEP (Table 19, Figure 29b, d), both of which are fitted to a bimodal equation, the 
dissociation constants for the tightest fit is similar. This makes it hard to determine if the TCEP or 
ThDP is having an effect, or if the effect is the difference in bimodal versus monomodal fitting. 
More replicates will be needed to work this out. In the presence of co-factor and substrate where 
a single binding curve is fitted (Figure 29e, f, Table 19) the Kd is slightly lower than apo protein 
alone (Figure 29a, Table 19) (and similar with and without TCEP) suggesting DHNA binding may 
be tighter in enzyme with co-factor and substrate present. The differences in curve fitting (bimodal 
versus single fitting) make it harder to directly compare and suggest more replicates are needed. 
However, we can conclude from these experiments the idea that DHNA does bind to Ec-MenD 
and a potential allosteric inhibition could be observed which has not been previously observed as 
the Ec-MenD structure shows the allosteric site is not well conserved. Further investigation into 
viewing this allosteric site is recommended to confirm the presence. 
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DHNA Binding to Ec-MenD 
DHNA Binding to Ec-MenD in the presence of TCEP 
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DHNA Binding to Ec-MenD in the presence of ThDP 
DHNA Binding to Ec-MenD in the presence of ThDP and TCEP 
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Figure 29: DHNA binding to Ec-MenD under various conditions. 1st Row(a): MgCl2 present 2nd Row 
(b): TCEP and MgCl2 present. 3rd Row(c): ThDP and MgCl2 present. 4th Row (d): ThDP, TCEP and 
MgCl2 present. 5th Row(e): ThDP, 2-oxoglutarate and MgCl2 present. 6th Row(f): ThDP, 2-oxoglutarate, 
TCEP and MgCl2 present. 
  
DHNA Binding to Ec-MenD in the presence of ThDP, 2-Oxoglutarate and TCEP  
DHNA Binding to Ec-MenD in the presence of ThDP and 2-Oxoglutarate 
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Table 19: Kd values of Ec-MenD under various DHNA binding conditions 
 








DHNA 50.9 1.3 - - 
DHNA with TCEP 
Present 
0.016 0.001 219.1 131.7 
DHNA with ThDP 
Present 
0.10 0.01 117.2 1.4 
DHNA with ThDP and 
TCEP Present 
0.12 0.01 71.7 0.5 
DHNA with ThDP and 
2-Oxoglutarate Present 
40.9 0.4 - - 
DHNA with ThDP, 2-
Oxoglutarate and 
TCEP Present 
48.4 0.3 - - 
 
4.4 IFQ Experiments with Smeg-MenD 
4.4.1 ThDP Binding 
Binding of ThDP to Smeg-MenD with the presence and absence of 2.5 mM TCEP displayed almost 
identical results. Clear binding is observed with both experiments fitting better to the bimodal 
equation. The affinity to the two binding sites is both within the same value ranges as each other, 
with the higher affinity binding site dissociation constants of 0.05 and 0.23 µM respectively and 
the lower affinity binding site Kd at 47.0 and 48 µM (Figure 30, Table 20). In conjunction with 
these differences being too insignificant to note, the lack of replicates in these experiments means 
that conclusions cannot be made. 
Table 20: Kd values of Smeg-MenD under various ThDP conditions 
 








ThDP 0.05 0.01 47.0 0.5 
ThDP with TCEP Present 0.23 0.01 48 2 
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Figure 30:  ThDP binding to Smeg-MenD under various conditions. Top (a): MgCl2 present. Bottom (b): 
TCEP and MgCl2 present. 
  
ThDP Binding to Smeg-MenD 
ThDP Binding to Smeg-MenD in the presence of TCEP 
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4.4.2 2-Oxoglutarate Binding 
Experiments involving 2-oxoglutarate with 100 µM ThDP presence in the protein buffer mix were 
again conducted in the presence and absence of 2.5 mM TCEP. In the absence of TCEP, 2-
oxoglutarate was observed to fit better to the bimodal equation with binding affinities very similar 
to the observed binding of ThDP (Figure 31a, Table 20). In the presence of TCEP, the bimodal 
equation no longer fits the binding curve best, however the single binding curve is not a perfect 
fit, suggesting bimodal binding might also be present here but not as clearly able to be fitted 
(Figure 31b). Both experiments demonstrate in the presence of ThDP the substrate 2-oxoglutarate 
can bind relatively strongly to Smeg-MenD (0.18/47 µM and 2.89 µM Table 21).  
Table 21: Kd values of Smeg-MenD under various 2-oxoglutarate conditions 
 










0.18 0.01 47 3 
2-Oxoglutarate with 
ThDP and TCEP Present 




Figure 31: 2-Oxoglutarate binding to Smeg-MenD under various conditions Top (a): ThDP and MgCl2 
present. Bottom (b): ThDP, TCEP and MgCl2 present. 
  
2-Oxoglutarate Binding to Smeg-MenD in the presence of ThDP 
2-Oxoglutarate Binding to Smeg-MenD in the presence of ThDP and TCEP 
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4.4.3 DHNA Binding 
Binding experiments of DHNA to Smeg-MenD provided identical results in both the presence and 
absence of TCEP (Figure 32 a and b).  With Kd values of 5.62 and 5.54 µM respectively, tight 
binding of DHNA to the Smeg-MenD can be confirmed. Due to a lack of replicate experiments, 
no major changes in enzyme activity due to TCEP presence can be proven or disproven. These 
results support the idea that DHNA successfully binds as an allosteric regulator similar to what is 
observed in Mtb-MenD.  
Further experimental work involving Smeg-MenD bound to ThDP (100 µM ThDP in the protein 
buffer mix) confirmed this theory. Without 2.5 mM TCEP presence DHNA binding fits best to the 
bimodal curve fitting equation, while in the presence of TCEP and in all other situations with 
ThDP present it appears to fit a single curve best. As we observe DHNA slowly oxidises over the 
course of the experiment this bimodal nature is hard to define as it could come from the enzyme 
which can exhibit asymmetry or the presence of oxidized forms of DHNA without TCEP. If we 
compare the non-bimodal experiment only, at a Kd of 4.69 µM, 1 µM less than the previous DHNA 
binding experiment with TCEP presence slightly tighter binding can be observed. Due to the lack 
of replicates and the value range between Kd still being in the micromolar range no firm 
conclusions can be made. 
The most significant differences observed in the DHNA experiments between TCEP absence and 
presence is observed with 100 µM ThDP and 2-oxoglutarate presence in the protein buffer mix. 
Without TCEP presence the Kd observed is 28.33 µM, approximately 5-fold higher than apo 
protein DHNA binding With TCEP presence, the Kd value experiences a 10-fold decrease to 2.84 
µM (Figure 32f), indicating tighter binding to Smeg-MenD with TCEP presence. Due to the lack 
of replicates, it is difficult to confirm this is the case and as such further experimentation would be 
required for more supporting evidence. What can be concluded from all the DHNA binding 
experiments for Smeg-MenD however is the successful binding of the allosteric regulator to Smeg-
MenD. This provides a new outlet for investigation of allosteric inhibitors and the characteristics 
of the MenD enzyme in all species. 
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DHNA Binding to Smeg-MenD 
DHNA Binding to Smeg-MenD in the presence of TCEP 
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DHNA Binding to Smeg-MenD in the presence of ThDP 
DHNA Binding to Smeg-MenD in the presence of ThDP and TCEP 
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Figure 32: DHNA binding to Smeg-MenD under various conditions. 1st Row(a): MgCl2 present 2nd 
Row(b): TCEP and MgCl2 present. 3rd Row(c): ThDP and MgCl2 present. 4th Row(d): ThDP, TCEP 
and MgCl2 present. 5th Row(e): ThDP, 2-oxoglutarate and MgCl2 present. 6th Row(f): ThDP, 2-
oxoglutarate, TCEP and MgCl2 present. 
  
DHNA Binding to Smeg-MenD in the presence of ThDP and 2-Oxoglutarate 
DHNA Binding to Smeg-MenD in the presence of ThDP, 2-Oxoglutarate and TCEP 
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Table 22: Kd values of Smeg-MenD under various DHNA conditions 
 








DHNA 5.62 0.04 - - 
DHNA with TCEP Present 5.54 0.08 - - 
DHNA with ThDP Present 0.16 0.02 150 10 
DHNA with ThDP and TCEP Present 4.69 0.03 - - 
DHNA with ThDP and 2-Oxoglutarate 
Present 
28.3 0.3 - - 
DHNA with ThDP, 2-Oxoglutarate and TCEP 
present 
2.84 0.04 - - 
 
4.5 Comparison of Binding Affinities Between Enzymes 
4.5.1 ThDP Binding 
None of the three MenD enzymes appear to display the exact same binding patterns as each other, 
but all three do have a confirmed high binding affinity condition for ThDP expected for a ThDP-
dependent enzyme. If we compare the Kd for ThDP (without TCEP) the binding affinity appears 
to be strongest for Smeg-MenD. This is because despite having a bimodal fit for the curve, 
considering the difference for both Kd values the higher Kd value is equal to the monomodal Kd 
observed from Sau-MenD. This is unlike Sau-MenD, Ec-MenD and Smeg-MenD show bimodal 
curves for ThDP binding without TCEP.  
Table 23: Calculated Kd values of ThDP experiments for MenD enzymes used in this work 
















4.5.2 2-Oxoglutarate Binding 
Due to the unavailability of one 2-oxoglutarate binding experimental data for Sau-MenD, it is 
more difficult to make direct comparisons between the three enzymes in this case. From the 
experimental data that is available it can be noted that only 2-oxoglutarate binding experiments of 
Smeg-MenD fit bimodal equation binding curve, specifically without TCEP addition. As there is 
no available data for the 2-oxoglutarate binding with ThDP presence and TCEP absence, we 
instead compare the Kd for 2-oxoglutarate binding with ThDP and TCEP presence. All three of 
these experiments have a monomodal fit for the curve, with the binding affinity between all three 
in a similar magnitude. This similar magnitude demonstrates consistently moderately tight binding 
of 2-oxoglutarate to all enzymes.  
Table 24: Calculated Kd values of 2-oxoglutarate experiments for MenD enzymes used in this work 
 Sau-MenD Ec-MenD Smeg-MenD 














4.5.3 DHNA Binding 
All three enzymes in this work demonstrated the potential for successful binding of DHNA. There 
does not appear to be any pattern in the binding between the enzymes despite this observation, 
such as no consistency in the curve fitting between enzymes. By comparing the Kd for DHNA 
(without TCEP) we can see that the binding affinity between Sau-MenD and Smeg-MenD are very 
similar and are both higher than observed in Ec-MenD. The Kd for Sau-MenD is 4.5 µM lower 
than Smeg-MenD, however these two values are in the same magnitude and so can be considered 
almost identical in terms of how tightly they bind DHNA.  
Mtb-MenD (carried out by Dr Ho) IFQ experiments done in replicate showed Kd of about 5 µM in 
to apo protein and increasing tight binding (lowering of Kd) with ThDP (down to ≈1µM) then 
ThDP and oxoglutarate (down to 0.3 µM). The results were similar with and without TCEP 
present.  
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Table 25: Calculated Kd values of DHNA experiments for MenD enzymes used in this work 














































4.6.1 Summary and Implications for Enzyme Activity and Regulation 
There is always more to learn about all enzymes and their activity, and the MenD enzyme is no 
different. This experimental work has demonstrated that interactions occurring in the MenD 
enzymes are diverse and certain binding characteristics that previously were not thought to be 
present may just require the right conditions to be observed. The binding of DHNA to all enzymes 
in this work is proof of this circumstance. This work provides key insight into the similarities in 
the MenD enzymes in terms of activity and binding sites regardless of the type of bacteria 
investigated (Gram-positive or Gram-negative). As such, regulatory work can also be conducted 
upon the variants of MenD enzyme and help to determine if any interactions that are observed in 
Mtb-MenD are unique to the enzyme or present in the wider family of MenD enzymes, which by 
extension can provide valuable target points for drug design. 
4.6.2 Limitations 
Unfortunately, due to time constraints for this work, none of the IFQ experiments were conducted 
in duplicate or triplicate. A consequence of this is that none of the results would be able to be 
published findings until this is done so and the observations made so far can be confirmed. It also 
means that many of the observations may not provide the actual results of the protein’s activity in 
these conditions. In addition to this, corrections were made for the inner filter effect assuming 
certain conditions, and as shown from the absence of the 2-oxoglutarate experiment with ThDP 
present in the buffer, some of the results provided very strange/unusable results. These would need 
to be revised and adjusted to achieve better results. 
4.6.3 Further Research  
Further research involving IFQ experimentation would be threefold. Firstly, repeat experiments of 
each result found in this work would be conducted in at least triplicate or higher to observe any 
deviations between experiments and firmly conclude the ideas discussed. Secondly, all 
experiments in this work utilised Mg2+ metal ions in the protein buffer mix. By changing the metal 
ions in the protein buffer mix and conducting the same experiments a clearer picture of the 
preferred metal ions for each MenD enzyme can be made and optimisation of the technique will 
be achieved. Finally, the experiments conducted upon the select MenD proteins in this work will 
be expanded to include additional MenD enzymes. This will help provide further insight into the 
similarities in activities between all MenD enzymes which will result in better drug design as a 
follow-on effect. 
83 
Chapter 5. Differential Scanning Fluorimetry of 
MenD from S. aureus, E. coli and, M. smegmatis 
5.1 Introduction 
5.1.1 Background 
Differential scanning fluorimetry (DSF) is an experimental technique that can be used to 
investigate the thermal stability of proteins.  It can investigate the effect on the melting temperature 
(Tm) of various additives to a protein. Detection of a positive (stabilising) or negative 
(destabilising) shift in the Tm of a protein can support the interaction of a protein with the additive. 
The amount of the protein and the concentration of the protein required are both low, allowing 
several experiments to be able to run with ease even in situations where protein aggregation has 
affected the final purified sample [71].  
The thermal unfolding of proteins is frequently monitored by the presence of a fluorescent dye. 
The most common dye used in DSF experiments is SYPRO orange, though many other dyes can 
be used as well. The fluorescent dye used in DSF experiments must be highly fluorescent in non-
polar environments such as those found in the hydrophobic sites of unfolded proteins compared to 
the aqueous solution [72]. SYPRO orange is favoured due to its high signal-to-noise ratio, 
demonstrating high increases in fluorescence in denatured protein compared to aqueous solution. 
In addition, SYPRO orange has a high excitation wavelength (500 nm) which decreases the 
chances for small molecule interference with dye fluorescence [71]. DSF is not without limitations, 
however. Interactions with the dye can occur despite being rare. These interactions can result in 
quenching of fluorescence intensity and a poor reading of the true Tm for the experiment. In 
addition, some DSF experiments fail to detect any ligand-protein binding. Despite these 
shortcomings, DSF is an extremely effective technique at detecting ligand-protein interactions and 
as such was a focus for the research in this chapter. 
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In this chapter, DSF was used to assess binding of different ligands and additives to three different 
MenD proteins (Sau-MenD, Ec-MenD, Smeg-MenD). Five 96-well plates were set up using a 
combination of natural ligands and substrates as well as some possible inhibitor candidates (Table 
26). The use of natural ligands and substrates that are confirmed to bind were used to determine 
how effective DSF is at detecting the binding of these additives and allows comparisons between 
the MenD proteins and how these proteins from different species interact with the same additives. 
Following on from these experiments, the potential inhibitor compounds as well as the natural 
regulator of Mtb-MenD (DHNA) were screened to determine if they bind to these three proteins.  
Table 26: All additives used in the DSF experiments with reason for use. 
Ligand/Additive Tested Reason 
TCEP Reducing agent, used to keep DHNA reduced in DHNA binding 
experiment. Tested by itself to see if it influenced the systems. 
DMSO Used to keep dissolve DHNA and inhibitors in binding experiment. 
Tested by itself to see if it influenced the systems. 
ThDP Co-factor, needed for reaction with 2-oxoglutarate in the enzyme 
active site to form intermediate 1. Tested by itself and with a 
variety of additives to see if it influences their binding. 
2-Oxoglutarate Substrate, reacts with ThDP in the enzyme active site to form 
intermediate 1, along with the loss of CO2. Tested by itself and 
with a variety of additives to see if it influences their binding. 
Metal ions Divalent metal ions required for co-factor to bind to protein. Some 
metal ions known to completely abolish activity. 
CHD Alternative substrate to the second substrate isochorismate, reacts 
with intermediate 1 in the enzyme active site, tested with ThDP and 
2-oxoglutarate. 
DHNA Allosteric regulator of Mtb-MenD, yet to be determined if it 
regulates other MenD proteins in the same way. Tested by itself 
and with a variety of additives to see if these influence its binding. 
5-Hydroxyinole carboxylic 
acid 
Potential inhibitor candidates. Structurally similar to allosteric 
regulator DHNA. Expected to bind to allosteric site 
1-Hydroxy-2-napthoic acid 







5.1.2 General Experimental Considerations and Controls 
The interaction of each MenD with various additives were screened across a number of DSF trays 
each containing 96 conditions. Each condition within the tray was measured in replicate (generally 
five technical replicates per condition). In addition, for accurate comparison of Tm control 
conditions were present on each tray (for example apo protein with no additive or protein with 
ThDP in later trays). This enables the differences in Tm to be measured within the same 
experimental tray and helped determine if any deviation in the Tm from the same condition 
occurred between experimental trays. 
5.2 DSF Experiments with Sau-MenD 
5.2.1 Apo with Additives 
Between the three identical apo protein experiments with no additives it is apparent that, while the 
latter two are in close agreement, the initial no additive apo condition has a lower Tm (Figure 33).  
This suggests some variability is possible between experiments and supports use of the apo control 
that matches that particular experiment to be used (as shown in Table 27, i.e. no additive (1) 
compared with additive conditions from the same experiment).   
With the addition of 1 mM TCEP a stabilisation effect was observed for Sau-MenD compared 
from the control no additive within that same experiment (no additive 1). However, this is not the 
case when taking into account Tm calculated from the apo protein without additives in the 
subsequent experiments (no additive 2 and 3). Experiments with higher concentrations of TCEP 
(2.5 mM TCEP) gave unclear melt curves with no agreement between the technical replicates and 
a Tm could not be determined. This may be due to an effect on the protein or an effect of higher 
levels of reducing agent on the experiment itself (e.g. on the dye used).  
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DMSO addition does not demonstrate any changes to the Tm of Sau-MenD, this is an important 
control to do for future experiments with ligands dissolved in DMSO as it suggests the presence 
of DMSO alone does not affect the protein’s Tm. With 0.1% DMSO and 2.5 mM TCEP present in 
the buffer however, a high Tm increase is observed. This is of particular interest due to the lack of 
data received from the 2.5 mM TCEP experiment, suggesting several possibilities, somehow 
DMSO may mitigate effects of TCEP either on the protein or to the experimental setup itself. 
 
Figure 33: Melting curve of Sau-MenD under apo conditions. This is an example of the replicates 
visualised for each condition during this work. Some experiments have fewer replicates than seen here. 
The top graph is the raw melt curve and the bottom graph the derivative melt curve. 
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Table 27: Melting temperature (Tm) of 5 µM Sau-MenD in different buffer conditions. The error is the 
standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm change. Tm and 
differences are measured in Celsius]. 
Additive(s) Tm Error Diff. Rel. To1 
No additive (1) 59.6 0.1   
No additive (2) 61.0 0.2 1.4 No additive (1) 
No additive (3) 60.7 0.3 1.1 No additive (1) 
1 mM TCEP 61.1 0.4 1.5 No additive (1) 
2.5 mM TCEP - -   
0.1% DMSO - -   
1% DMSO 60.7 0.3 0.0 No additive (3) 
0.1% DMSO, 2.5 mM TCEP 63.4 0.3 2.4 No additive (2) 
1 Compared to no additive conditions from the same experiment tray. 
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5.2.2 ThDP 
Binding of the co-factor ThDP to Sau-MenD was probed using DSF over a range of ThDP 
concentrations from 50–1000 µM in the presence and absence of the reducing agent TCEP (a ratio 
of between 1:10 protein to co-factor and 1:200 protein to cofactor). As divalent metal ions are 
required for ThDP to bind, 5 mM of MgCl2 was present in the buffer used for the DSF experiments. 
All experiments were performed with three to five technical replicates within the same tray and a 
standard error calculated that suggested in general any change in Tm from the appropriate control 
that was less than ~0.5 °C was within the noise of the experiment and not considered significant. 
In some cases, there was higher variability than others which could have arisen from additional 
factors causing added noise to the experiment. Some of these major causes could have been protein 
aggregation, pH drift, SYPRO dye affected by the cofactors and air bubbles, all of which would 
provide more variation in both Tm and standard error. 
In general, for ThDP experiments with no other additives we found that the addition of 
concentrations of less than 250 µM ThDP had very minor effects (maximum of 0.5 °C) on the Tm 
compared to the co-factor free apo protein control tested in the same experiment (Table 28). Higher 
concentrations (500 µM and 1000 µM) observed a change in temperature from co-factor free 
controls that were reproducible.  
 
Figure 34: Comparison of all ThDP concentrations present with Sau-MenD. As each experiment was 
conducted in replicate a representative result was selected. Apo condition was included. 
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The ThDP co-factor at 500 µM was tested in four different experiments (with five technical 
replicates for the first two experiments and three replicates for the remaining two) and in each case 
the Tm significantly increased for protein with ThDP added against apo conditions (Table 28). The 
majority of these experiments observed a Tm increase of 2.5-2.9 °C (with one exception 
demonstrating a Tm increase of only 1.4 °C (500 µM ThDP (1), Table 28)). This condition however 
also gave a higher standard error value suggesting variability in the measurement. Inspection of 
the melt curves for this experiment showed large variation between replicates (Figure 35). 
Addition of 1000 µM ThDP also demonstrated an increased Tm from the apo protein to a similar 
magnitude as 500 µM ThDP presence, suggesting saturation of the protein at 500 µM 
concentration. While a Tm change representing a genuine binding event would be expected to 
increase with the concentration of ligand it is possible that the binding of the protein is saturated 
by 500 µM ThDP (protein to ThDP molar ratio of 1:100).  It is possible that the concentrations 
between 250 and 500 µM may have shown this increasing effect but they were not tested in this 
work.  
 
Figure 35: Comparison of 500 µM ThDP addition to Sau-MenD in several plates. The binding of 500 
µM ThDP was also measured in the presence of reducing agent, TCEP. 
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The rationale behind this experiment was the need to keep redox active DHNA, which can oxidise 
over the course of several hours The goal was to see the effect of TCEP at two concentrations; 1 
mM as generally used in protein purification buffer and 2.5 mM as used in DHNA experiments 
where DHNA was being kept in the reduced form. When apo protein with TCEP present at 1 mM 
was compared to the same condition with 500 µM ThDP added, the temperature showed an 
increase similar, but slightly less, to that seen in the TCEP free experiments above, supporting the 
idea that Sau-MenD was able to bind to ThDP even when reducing agent was present (1.7 °C, 
Table 28). At 2.5 mM TCEP due to the variation observed between the replicates and no definitive 
peak for Tm observed, no temperature difference can be inferred for either apo conditions or with 
500 µM ThDP. This result at 2.5 mM could be due to effects on protein or potentially effects on 
the fluorescent signal from the SYPRO orange dye. 
The effect of DMSO in the presence of 500 µM ThDP was also measured. DMSO presence 
experiments were recorded due to the limited solubility of DHNA requiring it to be dissolved in 
DMSO. In order to give accurate readings upon the effect of DHNA to Tm, the effect of DMSO 
presence needs to be recorded for comparisons as well. Two concentrations of DMSO were used 
and tested, these were 0.1% and 1%. These experiments showed no significant changes to the Tm 
of Sau-MenD as seen in Table 28. An experiment looking at 500 µM ThDP, 0.1% DMSO and 2.5 
mM TCEP again showed no significant change. These results perhaps suggest that the TCEP 
concentration which causes instability is dependent upon other ligand presence or influences the 
SYPRO orange dye itself. Overall, the main finding that can be determined from these ThDP 
experiments is that the presence of ThDP stabilises the protein, resulting in the higher Tm. 
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Table 28: Melting temperature (Tm) of 5 µM Sau-MenD in different ThDP conditions. The error is the 
standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm change. Tm and 
differences are measured in Celsius]. 
Additive(s) Tm Error Diff. Rel. To1 
No additive (1) 59.6 0.1   
50 µM ThDP 60.0 0.2 0.4 No additive (1) 
100 µM ThDP 60.1 0.2 0.5 No additive (1) 
250 µM ThDP 59.8 0.2 0.2 No additive (1) 
500 µM ThDP (1) 61.0 0.8 1.4 No additive (1) 
500 µM ThDP (2) 62.4 0.4 2.8 No additive (1) 
500 µM ThDP (3) 62.4 0.1 2.9 No additive (1) 
500 µM ThDP (4) 62.0 0.4 2.5 No additive (1) 
1000 µM ThDP 62.2 0.1 2.7 No additive (1) 
500 µM ThDP, 1 mM TCEP 62.7 0.4 1.7 1 mM TCEP 
500 µM ThDP, 0.1% DMSO 62.2 0.5 0.2 500 µM ThDP (2) 
500 µM ThDP, 1% DMSO (2) 62.3 0.1 0.1 500 µM ThDP (2) 
500 µM ThDP, 0.1% DMSO, 2.5 mM TCEP 62.2 0.5 0.0 500 µM ThDP 
0.1% DMSO 
1 Compared to no additive conditions from the same experiment tray. 
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5.2.3 2-Oxoglutarate 
The effect of substrate 2-oxoglutarate, which reacts with the co-factor ThDP to form the first 
covalent intermediate, was then investigated for the effect upon the thermal stability of Sau-MenD. 
This substrate was investigated at a range of concentrations (50–1000 µM). Most experiments 
were undertaken in the presence of ThDP (generally at 500 µM) as ThDP is thought to be required 
for 2-oxoglutarate binding. One experiment investigated the effect of addition of high 
concentrations (1000 µM) of 2-oxoglutarate to apo protein, finding that there was an increase in 
Tm of 2.5 °C compared to apo protein. This suggests some possible binding or other stabilisation 
effects on the Sau-MenD protein in the absence of cofactor. When 500 µM ThDP is present with 
addition of 2-oxoglutarate a destabilising effect on the protein is instead observed, resulting in a 
consistent decrease in Tm.  
Closer inspection of the melt curves for these experiments showed a shoulder region, suggesting 
multiple melts for the protein as shown in Figure 36. This is less obvious at very high 2-
oxoglutarate concentration (1000 µM). This could be due to saturation of the enzyme at this high 
concentration and turnover is not fast enough. An experiment with 2.5 mM TCEP present in 
addition to 2-oxoglutarate and ThDP at 500 µM provided results which were inconclusive similar 





Figure 36: Melting curves of Sau-MenD with ThDP and 2-oxoglutarate binding. The shoulder region 
seen in these replicates demonstrates multiple melting events for the protein in these conditions. Shoulder 
region highlighted. 
An experiment was also conducted with both 0.1% DMSO and 2.5 mM TCEP present in addition 
to the 2-oxoglutarate and ThDP. There were no significant changes observed in these conditions, 
which is similar to the observed comparison between 500 µM ThDP, 0.1% DMSO and 2.5 mM 
TCEP conditions (Tables 28 and 29). The implication from these results is that TCEP activity does 
not appear to destabilise the reaction or make results difficult to obtain with DMSO present.  
Table 29: Melting temperature (Tm) of 5 µM Sau-MenD in different 2-oxoglutarate conditions. The error 
is the standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm change. 
Tm and differences are measured in Celsius]. 
Additive(s) Tm Error Diff. Rel. To1 
1000 µM 2-oxoglutarate 62.1 0.1 2.5 No additive (1) 
500 µM ThDP, 50 µM 2-oxoglutarate 61.0 0.4 -1.4 500 µM ThDP (2) 
500 µM ThDP, 100 µM 2-oxoglutarate 57.6 0.9 -4.8 500 µM ThDP (2) 
500 µM ThDP, 250 µM 2-oxoglutarate 59.5 0.6 -2.9 500 µM ThDP (2) 
500 µM ThDP, 500 µM 2-oxoglutarate 58.8 0.4 -3.6 500 µM ThDP (2) 
500 µM ThDP, 1000 µM 2-oxoglutarate 60.5 0.3 -1.9 500 µM ThDP (2) 
500 µM ThDP, 500 µM 2-oxoglutarate, 
2.5 mM TCEP 
- -   
500 µM ThDP, 500 µM 2-oxoglutarate, 
0.1% DMSO, 2.5 mM TCEP 
62.7 0.5 -0.1 500 µM ThDP 0.1% 
DMSO 2.5 mM TCEP (2) 
1 Compared to no additive conditions from the same experiment tray. 
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5.2.4 2,4-CHD 
2,4-Cylcohexadiene (2,4-CHD), an alternative substrate which mimics the highly unstable 
substrate isochorismate, was also investigated in a small number of experiments. Experiments 
involved either presence of 2,4-CHD at 500 µM with presence of 500 µM ThDP or the same 
conditions with 500 µM 2-oxoglutarate in addition. The experiment containing 500 µM ThDP and 
500 µM CHD showed a destabilisation effect upon the protein, with a decrease in Tm by 1.4 °C 
compared to one of the experiments with 500 µM ThDP present (Tables 28 and 30), while the 
experiment with 500 µM 2-oxoglutarate in addition to the previous substrates had a shoulder 
present as shown in Figure 37 very similar to what has been observed with the previous 2-
oxoglutarate experiments. The large Tm decreases observed for both experiments containing 2,4-
CHD (-1.4, -3.8 °C, Table 30) suggests that 2,4-CHD has a destabilising effect upon the protein, 
however the magnitude of the effect needs to be explored further. 
 
Figure 37: Melting curves of Sau-MenD with CHD, ThDP and 2-oxoglutarate. The shoulder region seen 




Table 30: Melting temperature (Tm) of 5 µM Sau-MenD in different CHD conditions. The error is the 
standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm change. Tm and 
differences are measured in Celsius]. 
Additive(s) Tm Error Diff. Rel. To1 
500 µM ThDP, 500 µM CHD 61.0 0.2 -1.4 500 µM ThDP (2) 
500 µM THDP, 500 µM CHD, 500 µM 2-
oxoglutarate 
58.6 0.2 -3.8 500 µM ThDP (2) 
1 Compared to no additive conditions from the same experiment tray. 
5.2.5 DHNA 
Exploring the potential binding interactions of MenD with DHNA was a focus of this work. As 
such, there are many more conditions tested with DHNA present compared to the other ligands. 
DHNA has some factors which complicate the DSF experimental results, as it has fluorescence of 
its own and is also not highly soluble. In order to minimise these issues a more modest 
concentration range from 5–100 µM was tested. The overall trend from DHNA addition was a 
destabilisation effect on the protein (Figure 38). At 5 µM, the results were inconclusive, however 
the trend from 10 µM to 100 µM, showed higher concentrations of DHNA resulting in larger 
decreases in Tm from 2.7–4.9 °C. Interestingly, a DHNA concentration of 50 µM demonstrated a 
slightly larger decrease in Tm than 100 µM, suggesting an optimal concentration of DHNA. At 30 
µM DHNA concentration a 1.9 °C decrease in Tm was observed. This was much less of a Tm 
decrease than the other DHNA experiments and against the overall trend observed. It is uncertain 
as to why this is the case, potentially alternative interactions were occurring at this concentration 
or experimental error is the explanation for this. 
Figure 38: Representative melting curves of increasing DHNA concentrations present with Sau-MenD. 
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Experiments in the presence of the reducing agent TCEP were also carried out. When compared 
to protein conditions of 2.5 mM TCEP and 0.1% DMSO presence which had already displayed an 
increased Tm of 2.4 °C compared to apo (2) the increase in Tm was a further 0.8–1.6 depending on 
the concentration. In these experiments, the lower concentrations of DHNA displayed larger 
increases than the higher DHNA concentrations (1.6 °C increase at 5 µM DHNA and 0.8 °C from 
50 µM DHNA). TCEP helps keep DHNA in a reduced form, so this potentially has an effect 
somehow on stabilising the protein. However, at the higher concentrations this stabilisation effect 
lessens and could end with a destabilisation effect gain at a high enough concentration (Figure 39). 
 
Figure 39: Comparison of melting curves for both DHNA binding and DHNA binding with TCEP 
presence for Sau-MenD.  
 
Experiments in the presence of ThDP (500 µM) with increasing DHNA concentration (5, 10, 50 
and 100 µM) were also conducted. With increasing concentration of DHNA and 500 µM ThDP 
presence a trend of decreasing Tm, and therefore a destabilisation of the protein was observed. 
These experiments were compared to the experiment containing 500 µM ThDP and 0.1% DMSO. 
The changes in Tm were high, with the lowest change being with 5 µM DHNA at 3.7 °C (Table 
31). Overall it demonstrates that in the presence of ThDP the destabilisation effect of DHNA is 
still present if not strengthened by ThDP presence.  
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Interestingly addition of 2.5 mM TCEP to the previous substrates of 500 µM ThDP and increasing 
DHNA concentration did not show the same destabilisation and in one case showed a stabilisation 
(100 µM DHNA concentration, showing a Tm increase of 1.8 °C). 
Experiments with DHNA involving both ThDP and 2-oxoglutarate at 500 µM being present with 
the varying concentration of DHNA were also conducted. Again, DHNA presence without TCEP 
has a destabilisation effect upon the protein, with the decrease in Tm, being as low as 2.9 °C in 10 
µM to as high as 4.5 °C in 50 µM (Table 31). At 5 µM the decrease in Tm is much higher than 
compared to 10 µM at 4.2 °C. It is uncertain as to why this is the case, however it is noted that the 
graphs for 10 µM have a distinguishable shoulder to the Tm peak, suggesting potential multiple 
melt sites (Figure 40). This could be further investigated to fully determine. With 2.5 mM TCEP 
addition to the other ligands, the stabilisation effect is again observed, in this case as an increase 
of Tm by 1 °C for all three DHNA concentrations. 
 
Figure 40: Melting curve of Sau-MenD with DHNA, ThDP and 2-oxoglutarate binding. The shoulder 
region seen in these replicates demonstrates multiple melting sites for the protein in these conditions. 
Shoulder region highlighted 
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Table 31: Melting temperature (Tm) of 5 µM Sau-MenD in different DHNA conditions. The error is the 
standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm change. Tm and 
differences are measured in Celsius. Derivative highlights the use of the derivative melt curves instead of 
Boltzmann melt curves for situations where the noise from the Boltzmann melt curves is too high]. 
Additive(s) Tm Error Diff. Rel. To1 
No additive (2) 61.0 0.2 1.4 No additive (1) 
10 µM DHNA 58.2 0.3 -2.8 No additive (2) 
20 µM DHNA 57.7 0.2 -3.2 No additive (2) 
30 µM DHNA 59.1 0.2 -1.9 No additive (2) 
50 µM DHNA 56.1 0.9 -4.9 No additive (2) 
100 µM DHNA 57.0 0.6 -4.0 No additive (2) 
5 µM DHNA, 2.5 mM TCEP 65.0 0.5 1.6 2.5 mM TCEP, 0.1% DMSO (2) 
10 µM DHNA, 2.5 mM TCEP 64.4 0.8 1.0 2.5 mM TCEP, 0.1% DMSO (2) 
30 µM DHNA, 2.5 mM TCEP 63.1 0.6 -0.2 2.5 mM TCEP, 0.1% DMSO (2) 
50 µM DHNA, 2.5 mM TCEP 64.2 1.0 0.8 2.5 mM TCEP, 0.1% DMSO (2) 
5 µM DHNA, 500 µM ThDP 60.8 0.1 -3.7 500 µM ThDP, 0.1% DMSO (2) 
(Derivative) 
10 µM DHNA, 500 µM ThDP 59.5 0.3 -5.0 500 µM ThDP, 0.1% DMSO (2) 
(Derivative) 
100 µM DHNA, 500 µM 
ThDP 
58.5 0.2 -6.0 500 µM ThDP, 0.1% DMSO (2) 
(Derivative) 
5 µM DHNA, 500 µM ThDP, 
2.5 mM TCEP 
64.5 0.1 -0.1 500 µM ThDP, 0.1% DMSO, 2.5 mM 
TCEP (2) (Derivative) 
10 µM DHNA, 500 µM ThDP, 
2.5 mM TCEP 
64.6 0.1 0.1 500 µM ThDP, 0.1% DMSO, 2.5 mM 
TCEP (2) (Derivative) 
50 µM DHNA, 500 µM ThDP, 
2.5 mM TCEP 
64.6 0.1 0.1 500 µM ThDP, 0.1% DMSO, 2.5 mM 
TCEP (2) (Derivative) 
100 µM DHNA, 500 µM 
ThDP, 2.5 mM TCEP 
66.3 0.3 1.8 500 µM ThDP, 0.1% DMSO, 2.5 mM 
TCEP (2) (Derivative) 
5 µM DHNA, 500 µM ThDP, 
500 µM 2-oxoglutarate 
60.3 0.1 -4.2 500 µM ThDP, 0.1% DMSO (2) 
(Derivative) 
10 µM DHNA, 500 µM ThDP, 
500 µM 2-oxoglutarate 
61.6 0.1 -2.9 500 µM ThDP, 0.1% DMSO (2) 
(Derivative) 
50 µM DHNA, 500 µM ThDP, 
500 µM 2-oxoglutarate 
60.0 0.2 -4.5 500 µM ThDP, 0.1% DMSO (2) 
(Derivative) 
5 µM DHNA, 500 µM ThDP, 
500 µM 2-oxoglutarate, 2.5 
mM TCEP 
65.5 0.1 1.1 500 µM ThDP, 500 µM 2-oxoglutarate, 
0.1% DMSO, 2.5 mM TCEP (2) 
(Derivative) 
10 µM DHNA, 500 µM ThDP, 
500 µM 2-oxoglutarate, 2.5 
mM TCEP 
65.4 0.1 1.0 500 µM ThDP, 500 µM 2-oxoglutarate, 
0.1% DMSO, 2.5 mM TCEP (2) 
(Derivative) 
50 µM DHNA, 500 µM ThDP, 
500 µM 2-oxoglutarate, 2.5 
mM TCEP 
65.6 0.09 1.1 500 µM ThDP, 500 µM 2-oxoglutarate, 
0.1% DMSO, 2.5 mM TCEP (2) 
(Derivative) 
1 Compared to no additive conditions from the same experiment tray. 
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5.2.6 Metals 
Although MgCl2 was added to the buffer solution for these experiments, three other metals were 
also investigated via DSF in this work. These metals (the salts MnCl2, CaCl2 and NiCl2) were all 
tested in apo conditions and in the presence of 500 µM ThDP at 5 mM concentrations. Both the 
apo conditions and the ThDP present conditions have no significant effects upon the Tm for both 
CaCl2 and MnCl2. However, NiCl2 demonstrates a significant destabilisation effect in both apo 
and ThDP conditions, with Tm decreases of 6.9 and 5.9 °C respectively. 
 
Figure 41: Representative melting curves for both NiCl2 binding experiments conducted with Sau-MenD. 
Table 32: Melting temperature (Tm) of 5 µM Sau-MenD in different Metal conditions. The error is the 
standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm change. Tm and 
differences are measured in Celsius]. 
Additive(s) Tm Error Diff. Rel. To1 
5 mM MnCl2 59.3 0.4 -0.3 No additive (1) 
5 mM MnCl2, 500 µM ThDP 62.8 0.1 0.4 500 µM ThDP (2) 
5 mM CaCl2 59.9 0.4 0.3 No additive (1) 
5 mM CaCl2, 500 µM ThDP 62.3 0.2 -0.1 500 µM ThDP (2) 
5 mM NiCl2 52.7 0.7 -6.9 No additive (1) 
5 mM NiCl2, 500 µM ThDP 56.5 0.2 -5.9 500 µM ThDP (2) 
1 Compared to no additive conditions from the same experiment tray. 
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5.2.7 Potential Inhibitors 
There are seven different potential inhibitors that were investigated in this work. These inhibitors 
were tested in both low and high concentrations (100 µM and 1000 µM) in both apo conditions 
and 500 µM ThDP concentration. The general trend of these potential inhibitors was found to be 
a destabilisation effect on the protein in both apo and ThDP conditions with little variation based 
on concentration. The most notable inhibitors for Sau-MenD appeared to be 2-naphtoic acid, 2-
hydroxy-1-naphtoic acid and 6-hydroxy-2-napthoic acid. 2-naphtoic acid showed the largest Tm 
changes between low concentration and high concentration in apo protein (low concentration Tm 
decrease of 1.5 °C and high concentration had a Tm increase of 1.2 °C). In addition, the presence 
of ThDP results in a decrease of 1.2 °C compared to the ThDP control conditions at low 
concentration. The high concentration results were inconclusive due to the variation between 
replicates; however, it would be interesting to replicate this experiment to potentially identify a 
similar effect in ThDP conditions. 
2-hydroxy-1-napthoic acid shows destabilisation effects in both apo and ThDP conditions, 
however in the presence of high concentration and 500 µM ThDP, this effect is much higher than 
all other conditions for this inhibitor at 1.6 °C. 
6-hydroxy-2-napthoic acid has a similar high Tm decrease compared to other conditions at high 
concentration and 500 µM ThDP at 1.3 °C. This suggests that these conditions may influence the 
protein, which may make it worth investigating for inhibitory purposes. 
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Table 33: Melting temperature (Tm) of 5 µM Sau-MenD in different Potential Inhibitor conditions. The 
error is the standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm 
change. Tm and differences are measured in Celsius]. 
Additive(s) Tm Error Diff. Rel. To1 
100 µM 5-hydroxyinole carboxylic 
acid 
58.3 0.1 -2.4 1% DMSO 
100 µM 1-hydroxy-2-napthoic acid 59.9 0.5 -0.8 1% DMSO 
1 mM 1-hydroxy-2-napthoic acid 59.7 0.1 -1.0 1% DMSO 
100 µM 1-hydroxy-2-napthoic acid, 
500 µM ThDP 
61.3 0.4 -1.0 500 µM ThDP, 1% DMSO 
1 mM 1-hydroxy-2-napthoic acid, 500 
µM ThDP 
61.6 0.5 -0.8 500 µM ThDP, 1% DMSO 
(Derivative) 
100 µM p-Phenylene diacetic acid 59.8 0.7 -0.9 1% DMSO (Derivative) 
1 mM p-Phenylene diacetic acid 60.1 0.4 -0.6 1% DMSO 
100 µM p-Phenylene diacetic acid, 500 
µM ThDP 
61.4 0.2 -0.8 500 µM ThDP, 1% DMSO 
1 mM p-Phenylene diacetic acid, 500 
µM ThDP 
62.4 0.3 0.1 500 µM ThDP, 1% DMSO 
100 µM Monobutyl phthalate 59.6 0.7 -1.1 1% DMSO 
1 mM Monobutyl phthalate 60.1 0.52 -0.6 1% DMSO 
100 µM Monobutyl phthalate, 500 µM 
ThDP 
61.8 0.47 -0.5 500 µM ThDP, 1% DMSO 
1 mM Monobutyl phthalate, 500 µM 
ThDP 
62.0 0.5 -0.3 500 µM ThDP, 1% DMSO 
100 µM 2-napthtoic acid 60.1 0.1 -1.5 1% DMSO (Derivative) 
1 mM 2-napthtoic acid 62.8 0.4 1.2 1% DMSO (Derivative) 
100 µM 2-napthtoic acid, 500 µM 
ThDP 
61.1 0.1 -1.2 500 µM ThDP, 1% DMSO 
100 µM 2-hydroxy-1-napthoic acid 61.2 0.1 -0.3 1% DMSO 
1 mM 2-hydroxy-1-napthoic acid 60.1 0.1 -0.6 1% DMSO 
100 µM 2-hydroxy-1-napthoic acid, 
500 µM ThDP 
62.0 0.1 -0.3 500 µM ThDP, 1% DMSO 
1 mM 2-hydroxy-1-napthoic acid, 500 
µM ThDP 
60.9 0.3 -1.6 500 µM ThDP, 1% DMSO 
(Derivative) 
1 mM 6-hydroxy-2-napthoic acid 60.7 1.3 -0.8 1% DMSO (Derivative) 
100 µM 6-hydroxy-2-napthoic acid, 
500 µM ThDP 
62.2 0.1 -0.3 500 µM ThDP, 1% DMSO 
(Derivative) 
1 mM 6-hydroxy-2-napthoic acid, 500 
µM ThDP 
60.9 0.2 -1.3 500 µM ThDP, 1% DMSO 
1 Compared to no additive conditions from the same experiment tray. 
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5.3 DSF Experiments with Ec-MenD 
5.3.1 Apo Conditions 
There were no major differences observed between the three apo condition experiments run unlike 
those observed in Sau-MenD. Ec-MenD in general appeared to be more stable upon addition of 
non-binding compounds to the buffer mix, with no major changes to the Tm observed from either 
TCEP addition or DMSO addition. The only condition which demonstrated a significant change 
was with a combination of 0.1% DMSO and 2.5 mM TCEP. A stabilisation effect was observed 
(1.1 °C, Table 34), suggesting the presence of both compounds having an additive effect upon Ec-
MenD. 
Table 34: Melting temperature (Tm) of 5 µM Ec-MenD in different buffer conditions. The error is the 
standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm change. Tm and 
differences are measured in Celsius]. 
Additive(s) Tm Error Diff. Rel. To1 
No additive (1)  54.9 0.1   
No additive (2)  55.1 0.0 0.2 No additive (1) (Derivative) 
No additive (3)  55.3 0.0 0.4 No additive (1) (Derivative) 
1 mM TCEP 55.4 0.1 0.5 No additive (1) (Derivative) 
2.5 mM TCEP 55.5 0.1 0.6 No additive (1) (Derivative) 
0.1% DMSO 54.6 0.1 -0.5 No additive (2) (Derivative) 
1% DMSO 55.0 0.1 -0.3 No additive (3) (Derivative) 
0.1% DMSO, 2.5 mM TCEP 56.2 0.1 1.1 No additive (2) (Derivative) 
1 Compared to no additive conditions from the same experiment tray. 
 
5.3.2 ThDP 
The overall trend with ThDP concentration increase observed for Ec-MenD is one of increasing 
stabilisation. The Tm increase is very high, with a lowest increase in the experiments with 
significant changes being 6.6 °C at 50 µM ThDP concentration (Table 35). There is a large 
difference between the repeated 500 µM ThDP experiments, with small to no change in three of 




Figure 42: Comparison of melting curves of Ec-MenD experiments involving 500 µM ThDP addition 
from various plates. 
 
TCEP addition does appear to provide a stabilisation effect, although without as significant of an 
effect on the protein as without ThDP present. While the experimental results for the 1 mM TCEP 
presence demonstrate a high Tm change, the standard error for this experiment is 6.9 which must 
be considered as imprecise for the results. Further experimentation work is needed. 
DMSO addition to Ec-MenD fails to provide any noteworthy effects upon the Tm of the protein, in 
addition to the condition 2.5 mM TCEP as well as 0.1% DMSO and 500 µM ThDP providing 
inconclusive results. Further experimentation may be required to investigate any potential 
interaction between DMSO and Ec-MenD. 
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Table 35: Melting temperature (Tm) of 5 µM Ec-MenD in different ThDP conditions. The error is the 
standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm change. Tm and 
differences are measured in Celsius]. 
Additive(s) Tm Error Diff. Rel. To1 
No additive (1)  54.9 0.1   
50 µM ThDP 51.3 1.5 6.6 No additive (1) 
100 µM ThDP 53.9 0.1 9.2 No additive (1) 
250 µM ThDP 53.27 0.03 8.55 No additive (1) 
500 µM ThDP (1) 53.3 0.1 8.6 No additive (1) 
500 µM ThDP (2) 53.84 0.04 0.54 No additive (1) 
500 µM ThDP (3) 53.6 0.10 0.3 No additive (1) 
500 µM ThDP (4) 53.9 0.0 0.6 No additive (1) 
1000 µM ThDP 53.9 0.1 9.2 No additive (1) 
500 µM ThDP, 1 mM TCEP 65.9 6.9 12.6 500 µM ThDP 
500 µM ThDP, 2.5 mM TCEP 58.5 0.5 1.9 2.5 mM TCEP 
500 µM ThDP, 0.1% DMSO 54.0 0.1 0.5 500 µM ThDP (2) 
500 µM ThDP, 1% DMSO 53.5 0.1 -0.4 1% DMSO 
500 µM ThDP, 0.1% DMSO, 2.5 mM 
TCEP 
Replicate   500 µM ThDP, 0.1% 
DMSO 
1 Compared to no additive conditions from the same experiment tray. 
 
5.3.3 2-Oxoglutarate 
Addition of 2-oxoglutarate demonstrates a significant Tm increase to both apo and ThDP bound 
Ec-MenD (Table 36). This suggests significant stabilisation effects from the 2-oxoglutarate 
substrate either during binding or when it reacts to form intermediate I.  
With 2.5 mM TCEP, 500 µM ThDP and 2-oxoglutarate present, a stabilisation effect is observed, 
with an increase of 6.9 °C. However, in the presence of 2.5 mM TCEP due to the large standard 
error no Tm change of note can be determined. 
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Table 36: Melting temperature (Tm) of 5 µM Ec-MenD in different 2-oxoglutarate conditions. The error 
is the standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm change. 
Tm and differences are measured in Celsius]. 
Additive(s) Tm Error Diff. Rel. To1 
1000 µM 2-oxoglutarate 53.0 0.0 8.3 No additive (1) 
500 µM ThDP, 50 µM 2-oxoglutarate 54.4 0.1 0.6 500 µM ThDP (2) 
500 µM ThDP, 100 µM 2-oxoglutarate 54.5 0.1 0.7 500 µM ThDP (2) 
500 µM ThDP, 250 µM 2-oxoglutarate 63.3 0.1 9.4 500 µM ThDP (2) 
500 µM ThDP, 500 µM 2-oxoglutarate 55.4 0.0 1.6 500 µM ThDP (2) 
500 µM ThDP, 1000 µM 2-oxoglutarate 62.3 0.1 8.4 500 µM ThDP (2) 
500 µM ThDP, 500 µM 2-oxoglutarate, 
2.5 mM TCEP 
62.3 0.2 6.9 500 µM ThDP, 500 µM 
2-oxoglutarate 
500 µM ThDP, 500 µM 2-oxoglutarate, 
0.1% DMSO, 2.5 mM TCEP 
56.6 2.0 2.6 500 µM ThDP, 0.1% 
DMSO, 2.5 mM TCEP 
(2) 
1 Compared to no additive conditions from the same experiment tray. 
 
5.3.4 CHD 
In relation to CHD presence for Ec-MenD, in the presence of 500 µM ThDP and CHD a minor Tm 
increase, and therefore a slight stabilisation effect is observed. Upon 500 µM 2-oxoglutarate 
addition, no discernible Tm change is observed. 
Table 37: Melting temperature (Tm) of 5 µM Ec-MenD in different CHD conditions. The error is the 
standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm change. Tm and 
differences are measured in Celsius]. 
Additive(s) Tm Error Diff. Rel. To1 
500 µM ThDP, 500 µM CHD 54.8 0.1 0.9 500 µM ThDP (2) 
500 µM THDP, 500 µM 
CHD, 500 µM 2-oxoglutarate 
55.1 0.1 0.3 500 µM ThDP (2) 




Many of the DHNA experiments did not provide clear results. This is due to a mixture of 
unreadable melt curves and replicate experiments not being in agreement with each other (see 
Appendix 2 for graphs) Most of these experiments will need to be repeated in further work due to 
this outcome, however some results are still available for discussion. 
This work shows that at DHNA concentrations above 10 µM destabilisation effects on Ec-MenD 
are observed. A maximum Tm decrease is observed at 50 µM DHNA concentration (-3.1 °C, Table 
38), suggesting an optimal DHNA concentration for Ec-MenD. This is supported by the decreasing 
Tm trend observed from 20-50 µM DHNA and with the lower decrease in Tm observed at 100 µM. 
As mentioned previously, many of the DHNA experiments for Ec-MenD will need to be repeated, 
as is the case for DHNA experiments in the presence of 2.5 mM TCEP. The only experiment in 
this set which provided usable results was at 100 µM DHNA concentration, where a significantly 
high Tm decrease was observed (19.7 °C, Table 38). while this could suggest the presence of TCEP 
allowing the redox active DHNA to interact with Ec-MenD in its full capacity, the lack of 
experimental results at lower DHNA concentrations makes it difficult to determine if this 
destabilization effect is an outlier or part of a trend. 
In the presence of 500 µM ThDP, increasing DHNA concentrations have almost no effect upon 
the Tm of the Ec-MenD protein. All four experiments as shown from 5-100 µM DHNA have no 
notable changes to the Tm. This is a large change from the high decreases of Tm found without 500 
µM ThDP presence, implying ThDP’s importance to the Ec-MenD protein for stabilisation. 
Two of the three experiments involving increasing DHNA concentration and 500 µM ThDP and 
2-oxoglutarate were also useable. 10 µM and 50 µM DHNA concentrations were recorded and 
while 50 µM did not have a mentionable Tm change, 10 µM DHNA demonstrated a high 
stabilisation effect upon Ec-MenD (5.8 °C, Table 38). This result is contradictory to the trends 
observed from all previous DHNA experiments for Ec-MenD, however due to the lack of results 
from most of the experiments it is difficult to determine if this is an outlier or similar to the previous 




Table 38: Melting temperature (Tm) of 5 µM Ec-MenD in different DHNA conditions. The error is the 
standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm change. Tm and 
differences are measured in Celsius]. For clarity only the conditions that gave interpretable results are 
shown in the table.  
Additive(s) Tm Error Diff. Rel. To1 
10 µM DHNA 52.73 0.04 -0.19 0.1% DMSO 
20 µM DHNA 51.3 0.1 -1.7 0.1% DMSO 
30 µM DHNA 50.5 0.9 -2.4 0.1% DMSO 
50 µM DHNA 49.8 0.1 -3.1 0.1% DMSO 
100 µM DHNA 51.5 0.1 -1.5 0.1% DMSO 
100 µM DHNA, 2.5 mM TCEP 27.4 0.1 -19.7 100 µM DHNA 
5 µM DHNA, 500 µM ThDP 54.2 0.1 0.2 500 µM ThDP, 0.1% 
DMSO (2) (Derivative) 
10 µM DHNA, 500 µM ThDP 54.38 0.03 0.36 500 µM ThDP, 0.1% 
DMSO (2) (Derivative) 
50 µM DHNA, 500 µM ThDP 54.11 0.04 0.09 500 µM ThDP, 0.1% 
DMSO (2) (Derivative) 
100 µM DHNA, 500 µM ThDP 54.5 0.1 0.5 500 µM ThDP, 0.1% 
DMSO (2) (Derivative) 
10 µM DHNA, 500 µM ThDP, 
500 µM 2-oxoglutarate 
59.8 0.2 5.8 500 µM ThDP, 0.1% 
DMSO (2) (Derivative) 
50 µM DHNA, 500 µM ThDP, 
500 µM 2-oxoglutarate 
54.5 0.1 0.5 500 µM ThDP, 0.1% 
DMSO (2) (Derivative) 
1 Compared to no additive conditions from the same experiment tray. 
 
5.3.6 Metals 
All three metal ions which were involved in the experiments demonstrated significant stabilisation 
effects in the absence of 500 µM ThDP. It should be noted that the NiCl2 condition did have a 
significantly high standard error of 9, meaning this result is not as reliable as the other metals. The 
result of this high error can be seen in Figure 43. With the presence of 500 µM ThDP, all three 
metal ions interacted differently. MnCl2 and NiCl2 both demonstrated a destabilisation effect to 




Figure 43: Melting curves of NiCl2 experiments conducted for Ec-MenD 
Table 39: Melting temperature (Tm) of 5 µM Ec-MenD in different Metal conditions. The error is the 
standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm change. Tm and 
differences are measured in Celsius]. 
Additive(s) Tm Error Diff. Rel. To1 
5 mM MnCl2 47.7 0.1 3.0 No additive (1) 
5 mM MnCl2, 500 µM ThDP 52.9 0.1 -0.9 500 µM ThDP (2) 
5 mM CaCl2 53.03 0.04 8.31 No additive (1) 
5 mM CaCl2, 500 µM ThDP 54.73 0.04 0.89 500 µM ThDP (2) 
5 mM NiCl2 54.7 9.0 10.0 No additive (1) 
5 mM NiCl2, 500 µM ThDP 41.4 0.3 -12.5 500 µM ThDP (2) 
1 Compared to no additive conditions from the same experiment tray. 
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5.3.7 Potential Inhibitors 
Most potential inhibitor experiments conducted for Ec-MenD did not provide any noteworthy 
changes. There are three inhibitors with experimental results of interest. 2-hydroxy-1-napthoic 
acid was observed with two destabilisation effects at both 100 µM and 1 mM 2-hydroxy-1-
napthoic acid concentration with 500 µM ThDP concentration present (-1.3 and -1.4 °C, Table 
40). At 1 mM p-Phenylene diacetic acid presence, a significantly high Tm decrease is observed 
which is not consistent with any of the other experiments conducted with this inhibitor. With a low 
standard error, this condition is worth further investigation as this is the highest Tm change 
observed from all experiments. Finally, 1 mM 1-hydroxy-2-naphthoic acid with 500 µM ThDP 
presence demonstrated the only large stabilisation effect observed from the potential inhibitors. 
(1.1 °C, Table 40). Further experimental work is worthwhile upon these three inhibitors for Ec-
MenD, as well as investigating the effects upon Tm these inhibitors have upon the different proteins 
involved in this work. 
Table 40: Melting temperature (Tm) of 5 µM Ec-MenD in different Potential Inhibitor conditions. The 
error is the standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm 
change. Tm and differences are measured in Celsius]. 
Additive(s) Tm Error Diff. Rel. To1 
100 µM 5-hydroxyinole carboxylic 
acid 
52.6 0.3 0.1 1% DMSO (Derivative) 
1 mM 5-hydroxyinole carboxylic acid 52.1 0.5 -0.4 1% DMSO (Derivative) 
100 µM 5-hydroxyinole carboxylic 
acid, 500 µM ThDP 
54.3 0.1 0.8 500 µM ThDP, 1% DMSO 
(Derivative) 
1 mM 5-hydroxyinole carboxylic 
acid, 500 µM ThDP 
54.0 0.1 0.5 500 µM ThDP, 1% DMSO 
(Derivative) 
100 µM 1-hydroxy-2-napthoic acid 53.0 0.3 0.5 1% DMSO (Derivative) 
1 mM 1-hydroxy-2-napthoic acid 52.2 1.0 -0.3 1% DMSO (Derivative) 
100 µM 1-hydroxy-2-napthoic acid, 
500 µM ThDP 
54.4 0.2 0.9 500 µM ThDP, 1% DMSO 
(Derivative) 
1 mM 1-hydroxy-2-napthoic acid, 
500 µM ThDP 
54.6 0.3 1.1 500 µM ThDP, 1% DMSO 
(Derivative) 
100 µM p-Phenylene diacetic acid 52.8 0.1 0.4 1% DMSO (Derivative) 
1 mM p-Phenylene diacetic acid 20.6 0.3 -32.7 1% DMSO (Derivative) 
100 µM p-Phenylene diacetic acid, 
500 µM ThDP 
53.1 0.1 0.6 500 µM ThDP, 1% DMSO 
(Derivative) 
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1 mM p-Phenylene diacetic acid, 500 
µM ThDP 
53.0 0.1 0.5 500 µM ThDP, 1% DMSO 
(Derivative) 
100 µM Monobutyl phthalate 54.2 0.0 0.7 1% DMSO (Derivative) 
1 mM Monobutyl phthalate 54.2 0.1 0.7 1% DMSO (Derivative) 
100 µM Monobutyl phthalate, 500 
µM ThDP 
53.0 0.1 0.6 500 µM ThDP, 1% DMSO 
(Derivative) 
1 mM Monobutyl phthalate, 500 µM 
ThDP 
53.0 0.1 0.5 500 µM ThDP, 1% DMSO 
(Derivative) 
100 µM 2-napthtoic acid 54.2 0.0 0.7 1% DMSO (Derivative) 
1 mM 2-napthtoic acid 54.0 0.1 0.5 1% DMSO (Derivative) 
100 µM 2-napthtoic acid, 500 µM 
ThDP 
53.0 0.1 0.6 500 µM ThDP, 1% DMSO 
(Derivative) 
1 mM 2-napthtoic acid, 500 µM 
ThDP 
52.7 0.4 0.3 500 µM ThDP, 1% DMSO 
(Derivative) 
100 µM 2-hydroxy-1-napthoic acid 54.2 0.0 0.7 1% DMSO (Derivative) 
1 mM 2-hydroxy-1-napthoic acid 54.0 0.1 0.5 1% DMSO (Derivative) 
100 µM 2-hydroxy-1-napthoic acid, 
500 µM ThDP 
51.2 0.7 -1.3 500 µM ThDP, 1% DMSO 
(Derivative) 
1 mM 2-hydroxy-1-napthoic acid, 
500 µM ThDP 
51.0 0.9 -1.4 500 µM ThDP, 1% DMSO 
(Derivative) 
100 µM 6-hydroxy-2-napthoic acid 53.9 0.1 0.4 1% DMSO (Derivative) 
1 mM 6-hydroxy-2-napthoic acid 53.9 0.1 0.4 1% DMSO (Derivative) 
100 µM 6-hydroxy-2-napthoic acid, 
500 µM ThDP 
53.1 0.1 0.6 500 µM ThDP, 1% DMSO 
(Derivative) 
1 mM 6-hydroxy-2-napthoic acid, 
500 µM ThDP 
53.0 0.1 0.5 500 µM ThDP, 1% DMSO 
(Derivative) 
1 Compared to no additive conditions from the same experiment tray. 
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5.4 DSF Experiments with Smeg-MenD 
5.4.1 Apo Conditions 
Apo conditions for Smeg-MenD showed minimal changes to the Tm between the three conditions. 
A decrease was observed in the third set of experiments; however, this change was relatively small. 
Addition of TCEP provided nothing of note at 1 mM TCEP, while at higher concentration of 2.5 
mM although a large decrease was observed the standard error for this experiment was sufficiently 
high to disregard this result due to inaccuracies. DMSO addition provided no Tm changes worth 
mentioning, while with DMSO and TCEP presence, the standard error was again too high to 
effectively use this result in this discussion. 
Table 41: Melting temperature (Tm) of 5 µM Smeg-MenD in different buffer conditions. The error is the 
standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm change. Tm and 
differences are measured in Celsius]. 
Additive(s) Tm Error Diff. Rel. To1 
No additive (1) 59.6 0.2   
No additive (2) 59.8 0.0 0.2 No additive (1) (Derivative) 
No additive (3) 59.0 0.0 -0.6 No additive (1) (Derivative) 
1 mM TCEP 59.6 0.2 0 No additive (1) (Derivative) 
2.5 mM TCEP 55.6 2.4 -4 No additive (1) (Derivative) 
0.1% DMSO 59.5 0.1 -0.1 No additive (2) (Derivative) 
1% DMSO 59.4 0.2 0.4 No additive (3) (Derivative) 
0.1% DMSO, 2.5 mM TCEP 57.8 1.1 2 No additive (2) (Derivative) 
1 Compared to no additive conditions from the same experiment tray. 
5.4.2 ThDP 
It is not until a ThDP concentration of 250 µM is present that a significant Tm change is observed 
in Smeg-MenD. At this concentration a major destabilisation effect occurs for Smeg-MenD, which 
is the most significant change observed from any concentration of ThDP addition. (-18.2 °C, Table 
42). It should be noted however that this large decrease in Tm is accompanied by a large standard 
error of 5 and as such must be observed under some scrutiny on the precision of this result (Figure 
44). The remaining experiments with solely ThDP addition to Smeg-MenD do not appear to follow 
any specific stabilisation or destabilisation trend. Of the four repeated experiments at 500 µM 
ThDP concentration, the only Tm changes of increase are destabilisation results, and only one of 
these shows a significant change. Conversely, at 1000 µM ThDP concentration a Tm increase 
comparative to the decrease seen at 500 µM ThDP concentration was observed (-3.1 vs 2.3 °C, 
Table 42), suggesting no particular trend in the effects of ThDP on Smeg-MenD. 
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Figure 44: Melting curves of all ThDP concentrations for Smeg-MenD. As can be seen the large error 
observed at 250 µM concentration corresponds accordingly to a melt curve significantly different than the 
other ThDP concentrations. 
 
A significant change occurs in the 2.5 mM TCEP 500 µM ThDP condition. A destabilisation effect 
is observed (-2 °C, Table 42).  With 1 mM TCEP addition no major changes in Tm are observed. 
DMSO addition provides interesting results. At 0.1 % DMSO concentration a high Tm increase is 
observed whilst in the presence of 500 µM ThDP, whereas at a higher concentration of DMSO 
(1%) this stabilisation effect is absent (3.3 vs -0.9 °C, Table 42). This could be due to an ideal 
DMSO concentration for Smeg-MenD interactions. 2.5 mM TCEP presence does not appear to 
have any meaningful effect upon the Tm of Smeg-MenD. 
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Table 42: Melting temperature (Tm) of 5 µM Smeg-MenD in different ThDP conditions. The error is the 
standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm change. Tm and 
differences are measured in Celsius]. 
Additive(s) Tm Error Diff. Rel. To1 
No additive (1) 59.6 0.2   
50 µM ThDP 59.7 0.1 0.1 No additive (1) (Derivative) 
100 µM ThDP 59.7 0.2 0.1 No additive (1) (Derivative) 
250 µM ThDP 41.4 5.0 -18.2 No additive (1) (Derivative) 
500 µM ThDP (1) 58.9 0.9 -0.7 No additive (1) (Derivative) 
500 µM ThDP (2) 56.9 0.1 0.2 No additive (1) (Derivative) 
500 µM ThDP (3) 59.8 0.1 -3.1 No additive (1) (Derivative) 
500 µM ThDP (4) 60.1 0.1 0.5 No additive (1) (Derivative) 
1000 µM ThDP 56.2 0.3 2.3 No additive (1) (Derivative) 
500 µM ThDP, 1 mM TCEP 59.7 0.1 0.1 1 mM TCEP 
500 µM ThDP, 2.5 mM 
TCEP 
57.6 0.8 -2.0 2.5 mM TCEP 
500 µM ThDP, 0.1% DMSO 59.8 0.1 3.3 500 µM ThDP (3) 
500 µM ThDP, 1% DMSO 59.0 0.2 -0.9 500 µM ThDP (1) 
500 µM ThDP, 0.1% DMSO, 
2.5 mM TCEP 
59.3 0.4 -0.5 500 µM ThDP, 0.1% 
DMSO 
1 Compared to no additive conditions from the same experiment tray. 
5.4.3 2-Oxoglutarate 
2-Oxoglutarate does not appear to display much of a change in the Tm of Smeg-MenD at any 
concentration. The most significant change observed in the Tm is observed at 250 µM 2-
oxoglutarate concentration with 500 µM ThDP presence. The change observed at this 
concentration is slightly higher than what is observed with only 1000 µM 2-oxoglutarate presence 
for Smeg-MenD, potentially suggesting a saturation concentration of 2-oxoglutarate while in the 
presence of ThDP. 2.5 mM TCEP addition also does not provide any noteworthy Tm changes for 
Smeg-MenD, and the significantly high Tm increase seen with ThDP, 2-oxoglutarate, DMSO and 
TCEP presence is accompanied by an even higher standard error, rendering this result far too 
inaccurate for use. 
The experiment involving 0.1% DMSO addition in addition to 500 µM ThDP and 2-oxoglutarate 
and 2.5 mM TCEP has a standard error both higher than the Tm difference and the accepted 
standard error, meaning this experiment has unusable results for this experiment.  
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Table 43: Melting temperature (Tm) of 5 µM Smeg-MenD in different 2-oxoglutarate conditions. The 
error is the standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm 
change. Tm and differences are measured in Celsius]. 
Additive(s) Tm Error Diff. Rel. To1 
1000 µM 2-oxoglutarate 60.2 0.1 0.6 No additive (1) (Derivative) 
500 µM ThDP, 50 µM 2-
oxoglutarate 
60.0 0.1 0.3 500 µM ThDP (2) (Derivative) 
500 µM ThDP, 100 µM 2-
oxoglutarate 
59.7 0.1 0.0 500 µM ThDP (2) (Derivative) 
500 µM ThDP, 250 µM 2-
oxoglutarate 
57.8 0.3 0.9 500 µM ThDP (2) 
500 µM ThDP, 500 µM 2-
oxoglutarate 
60.1 0.1 0.4 500 µM ThDP (2) (Derivative) 
500 µM ThDP, 1000 µM 2-
oxoglutarate 
59.9 0.1 0.2 500 µM ThDP (2) (Derivative) 
500 µM ThDP, 500 µM 2-
oxoglutarate, 2.5 mM TCEP 
60.3 0.1 0.1 500 µM ThDP, 1000 µM 2-
oxoglutarate 
500 µM ThDP, 500 µM 2-
oxoglutarate, 0.1% DMSO, 2.5 mM 
TCEP 
64.7 5.5 5.3 500 µM ThDP, 0.1% DMSO, 
2.5 mM TCEP (2) 
1 Compared to no additive conditions from the same experiment tray. 
5.4.4 CHD 
CHD was not a ligand of major focus in this work, but the results provided from the experiments 
warranted further discussion. In a trend like the results observed from the 2-oxoglutarate 
experiments the CHD binding experiments demonstrated destabilisation effects in Sau-MenD, and 
stabilisation effects in Ec-MenD and Smeg-MenD, with a greater stabilisation effect (Tm increase) 
observed in Ec-MenD. This result could be due to the presence of ThDP and 2-oxoglutarate in 
addition to CHD, however as the Tm differences were compared to ThDP binding experiments 
with similar concentration this can at least eliminate the possibility that all that is observed is ThDP 
binding effects. CHD could be affecting the proteins through either binding to the ligands prior to 
interactions, direct protein interaction, or a mixture of both. Regardless, these results suggest that 
further CHD experimentation is needed for better characterisation of the MenD enzyme. 
Table 44: Melting temperature (Tm) of 5 µM Smeg-MenD in different CHD conditions. The error is the 
standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm change. Tm and 
differences are measured in Celsius]. 
Additive(s) Tm Error Diff. Rel. To1 
500 µM ThDP, 500 µM CHD 60.1 0.1 0.3 500 µM ThDP (2) (Derivative) 
500 µM THDP, 500 µM 
CHD, 500 µM 2-oxoglutarate 
60.0 0.1 -0.1 500 µM ThDP (2) (Derivative) 
1 Compared to no additive conditions from the same experiment tray. 
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5.4.5 DHNA 
Significant changes to the Tm were observed upon addition of increasing DHNA concentrations. 
These destabilisation effects occurred at 10 µM DHNA concentration through to 100 µM DHNA 
and as shown in Table 45 ranged from a Tm decrease of 24.4 – 32.7 °C. The presence of 2.5 mM 
TCEP appears to not only fully negate the destabilisation effects of DHNA seen previously, but 
also provide stabilisation effects upon Smeg-MenD (Figure 45).  The only exception is at 30 µM 
DHNA concentration which maintained a destabilisation effect of -14.9 °C but also had the highest 
standard error as well. These results are quite supportive of the theory that DHNA requires the 
presence of TCEP to maintain redox activity, as these two results are drastically different. Further 
investigation potentially using different reducing agents to determine if this effect is purely due to 
the DHNA being redox active or the reducing agent is having an additional effect could prove to 
be useful to this work. 
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Figure 45: Top (a): Comparisons of melting curves for all DHNA concentrations to Smeg-MenD. 
Bottom (b): Comparisons of melting curves for all DHNA concentrations with 2.5 mM TCEP present for 
Smeg-MenD. 
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The presence of 500 µM ThDP with an increasing DHNA concentration had an interesting effect 
on the Smeg-MenD protein. DHNA concentrations of 5 and 50 µM whilst having large 
destabilisation effects upon Smeg-MenD have equally high standard errors, resulting in unusable 
results for discussion. At 10 µM and 100 µM DHNA, stabilisation effects of vastly different 
magnitudes were observed. Due to the incredibly high Tm increase observed at 100 µM DHNA 
concentration, further experimentation at higher DHNA concentrations would provide more 
accurate information on the optimal concentration needed for the Smeg-MenD protein, and MenD 
proteins in general. Regardless, it is apparent that higher DHNA presence at this point have only 
provided more significant changes to Tm and as such finding the upper limit would be beneficial. 
2.5 mM TCEP addition follows the same trend as seen before with all concentrations having 
stabilisation effects, with the Tm increase at 100 µM DHNA being significantly higher.  
The presence of 500 µM 2-oxoglutarate has very negative effects upon the experimentation work, 
resulting in high standard errors in all experiments. This suggests reproducibility between 
replicates is very poor and as such most of these results cannot be used to discern anything of use. 
This also appear to be the case for the same experiments with 2.5 mM TCEP presence. Appendix 
3 shows the poor reproducibility in replicates. The only exception to this is found at 10 µM DHNA 
concentration with 2.5 mM presence. At this concentration as low error is observed while a high 
Tm decrease can be seen. Further experimentation around these conditions need to be done to 
determine if the presence of 2-oxoglutarate does result in this destabilisation effect observed. 
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Table 45: Melting temperature (Tm) of 5 µM Smeg-MenD in different DHNA conditions. The error is the 
standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm change. Tm and 
differences are measured in Celsius]. 
Additive(s) Tm Error Diff. Rel. To 
5 µM DHNA 60.1 0.1 0.5 0.1% DMSO (Derivative) 
10 µM DHNA 25.3 0.2 -29.3 0.1% DMSO 
20 µM DHNA 26.8 0.2 -32.7 0.1% DMSO (Derivative) 
30 µM DHNA 33.8 0.2 -25.8 0.1% DMSO (Derivative) 
50 µM DHNA 30.2 0.6 -29.4 0.1% DMSO (Derivative) 
100 µM DHNA 30.1 0.5 -24.4 0.1% DMSO (Derivative) 
5 µM DHNA, 2.5 mM TCEP 60.0 0.1 2.2 2.5 mM TCEP, 0.1% DMSO 
(Derivative) 
10 µM DHNA, 2.5 mM TCEP 59.4 0.1 1.6 2.5 mM TCEP, 0.1% DMSO 
(Derivative) 
20 µM DHNA, 2.5 mM TCEP 60.54 0.05 2.7 2.5 mM TCEP, 0.1% DMSO 
(Derivative) 
30 µM DHNA, 2.5 mM TCEP 40.6 2.4 -14.9 2.5 mM TCEP, 0.1% DMSO 
50 µM DHNA, 2.5 mM TCEP 60.1 0.1 2.3 2.5 mM TCEP, 0.1% DMSO 
100 µM DHNA, 2.5 mM TCEP 60.66 0.06 2.8 2.5 mM TCEP, 0.1% DMSO 
(Derivative) 
5 µM DHNA, 500 µM ThDP 53.8 6.5 -6.0 500 µM ThDP, 0.1% DMSO 
(2) (Derivative) 
10 µM DHNA, 500 µM ThDP 60.6 0.1 0.8 500 µM ThDP, 0.1% DMSO 
(2) (Derivative) 
50 µM DHNA, 500 µM ThDP 49.9 12.0 -10.0 500 µM ThDP, 0.1% DMSO 
(2) (Derivative) 
100 µM DHNA, 500 µM ThDP 83.1 0.3 23.3 500 µM ThDP, 0.1% DMSO 
(2) (Derivative) 
5 µM DHNA, 500 µM ThDP, 2.5 
mM TCEP 
59.5 0.4 0.2 500 µM ThDP, 0.1% DMSO, 
2.5 mM TCEP (2) (Derivative) 
10 µM DHNA, 500 µM ThDP, 2.5 
mM TCEP 
60.9 0.3 1.6 500 µM ThDP, 0.1% DMSO, 
2.5 mM TCEP (2) (Derivative) 
50 µM DHNA, 500 µM ThDP, 2.5 
mM TCEP 
60.9 0.2 1.5 500 µM ThDP, 0.1% DMSO, 
2.5 mM TCEP (2) (Derivative) 
100 µM DHNA, 500 µM ThDP, 2.5 
mM TCEP 
88.9 0.4 29.6 500 µM ThDP, 0.1% DMSO, 
2.5 mM TCEP (2) (Derivative) 
5 µM DHNA, 500 µM ThDP, 500 
µM 2-oxoglutarate 
56.6 8.5 -3.2 500 µM ThDP, 0.1% DMSO 
(Derivative) 
10 µM DHNA, 500 µM ThDP, 500 
µM 2-oxoglutarate 
57.2 11.6 -0.2 500 µM ThDP 
0.1% DMSO 
50 µM DHNA, 500 µM ThDP, 500 
µM 2-oxoglutarate 
44.3 14.5 -15.5 500 µM ThDP, 0.1% DMSO 
(Derivative) 
5 µM DHNA, 500 µM ThDP, 500 
µM 2-oxoglutarate, 2.5 mM TCEP 
50.2 7.6 -7.1 500 µM ThDP, 500 µM 2-
oxoglutarate, 0.1% DMSO, 2.5 
mM TCEP 
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10 µM DHNA, 500 µM ThDP, 500 
µM 2-oxoglutarate, 2.5 mM TCEP 
60.7 0.3 -3.9 500 µM ThDP, 500 µM 2-
oxoglutarate, 0.1% DMSO, 2.5 
mM TCEP (Derivative) 
50 µM DHNA, 500 µM ThDP, 500 
µM 2-oxoglutarate, 2.5 mM TCEP 
64.0 3.3 -0.7 500 µM ThDP, 500 µM 2-
oxoglutarate, 0.1% DMSO, 2.5 
mM TCEP (Derivative) 
1 Compared to no additive conditions from the same experiment tray. 
 
5.4.6 Metals 
Due to the large standard errors observed in the NiCl2 results for Smeg-MenD, these have been 
omitted from the discussion on effects by the metals.  
Addition of either metal at 5 mM concentration interestingly has the exact same effect upon the 
Tm of Smeg-MenD. Both metals display a Tm increase and therefore a stabilisation effect to Smeg-
MenD (3.6 °C, Table 46). This same effect between the added metals is not observed in the 
presence of 500 µM ThDP. While MnCl2 demonstrates no noteworthy Tm change CaCl2 has a Tm 
increase lower than without ThDP presence (1.6 vs 3.6 °C, Table 46). Further investigation into 
the optimal metals to be used in the buffer solution could be useful as this could have a more 
significant effect upon the interactions of Smeg-MenD with the other ligands investigated in this 
work. 
Table 46: Melting temperature (Tm) of 5 µM Smeg-MenD in different metal conditions. The error is the 
standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm change. Tm and 
differences are measured in Celsius]. 
Additive(s) Tm Error Diff. Rel. To1 
5 mM MnCl2 57.5 0.4 3.6 No additive (1) 
5 mM MnCl2, 500 µM ThDP 56.8 0.8 -0.1 500 µM ThDP (2) 
5 mM CaCl2 57.5 0.2 3.6 No additive (1) 
5 mM CaCl2, 500 µM ThDP 58.5 0.2 1.6 500 µM ThDP (2) 
5 mM NiCl2 43.9 6.9 10.0 No additive (1) 
5 mM NiCl2, 500 µM ThDP 53.4 1.7 -6.4 500 µM ThDP (2) (Derivative) 
1 Compared to no additive conditions from the same experiment tray. 
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5.4.7 Potential Inhibitors 
All potential inhibitors tested demonstrated considerable Tm changes for Smeg-MenD, which is an 
interesting outcome due to the similarity between Smeg-MenD and Mtb-MenD in structure and 
origin. The results observed from Smeg-MenD may be more indicative of what would be expected 
to be seen from Mtb-MenD and so further optimisation and investigation into particular potential 
inhibitors have more importance in reference to Smeg-MenD. While the majority of the 
experiments demonstrated Tm increases of approximately 2 °C, there are some inhibitors in which 
only one result was usable for this work and some in which the standard error is too high to be 
considered a useful result as well. The inhibitors that should be considered for further investigation 
are p-phenylene diacetic acid, monobutyl phthalate, and 2-hydroxy-1-napthoic acid. Both 
monobutyl phthalate and 2-hydroxy-1-napthoic acid provided the only full results with no high 
standard error and consistent stabilisation effects upon Smeg-MenD, suggesting interactions 
between the protein and ligand. P-Phenylene diacetic acid also appears to have this same Tm 
increase effect but at a higher change, however at 1 mM p-Phenylene diacetic acid concentration 
with 500 µM ThDP presence the standard error of the experiment is too high to be usable and so 
further investigation to confirm the interaction between Smeg-MenD and this condition could 
provide leads on the most likely alternative inhibitor for the protein.  
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Table 47: Melting temperature (Tm) of 5 µM Smeg-MenD in different potential inhibitor conditions. The 
error is the standard error of the mean. [A dash (-) signifies data unavailable due to an unreadable Tm 
change. Tm and differences are measured in Celsius]. 
Additive(s) Tm Error Diff. Rel. To1 
100 µM 5-hydroxyinole carboxylic 
acid 
54.7 1.9 -4.7 1% DMSO 
100 µM 1-hydroxy-2-napthoic acid 57.5 5.2 -1.9 1% DMSO 
1 mM 1-hydroxy-2-napthoic acid 60.6 0.2 1.6 1% DMSO 
100 µM 1-hydroxy-2-napthoic acid, 
500 µM ThDP 
61.2 0.2 2.3 500 µM ThDP, 1% DMSO 
1 mM 1-hydroxy-2-napthoic acid, 
500 µM ThDP 
58.3 3.8 -1.1 500 µM ThDP, 1% DMSO 
(Derivative) 
100 µM p-phenylene diacetic acid 62.7 0.2 3.4 1% DMSO (Derivative) 
1 mM p-phenylene diacetic acid 62.3 0.3 3.4 1% DMSO 
100 µM p-phenylene diacetic acid, 
500 µM ThDP 
62.2 0.1 3.3 500 µM ThDP, 1% DMSO 
1 mM p-phenylene diacetic acid, 500 
µM ThDP 
57.8 3.8 -1.6 500 µM ThDP, 1% DMSO 
100 µM monobutyl phthalate 61.3 0.3 2.0 1% DMSO 
1 mM monobutyl phthalate 62.1 0.2 3.2 1% DMSO 
100 µM monobutyl phthalate, 500 
µM ThDP 
61.6 0.1 2.6 500 µM ThDP, 1% DMSO 
1 mM monobutyl phthalate, 500 µM 
ThDP 
61.6 0.1 2.3 500 µM ThDP, 1% DMSO 
100 µM 2-napthtoic acid 61.0 0.3 1.6 1% DMSO (Derivative) 
1 mM 2-napthtoic acid 61.7 0.1 2.8 1% DMSO (Derivative) 
100 µM 2-napthtoic acid, 500 µM 
ThDP 
61.3 0.1 2.4 500 µM ThDP, 1% DMSO 
100 µM 2-hydroxy-1-napthoic acid 61.4 0.1 2.1 1% DMSO 
1 mM 2-hydroxy-1-napthoic acid 60.8 0.1 1.4 1% DMSO 
100 µM 2-hydroxy-1-napthoic acid, 
500 µM ThDP 
62.1 0.1 3.1 500 µM ThDP, 1% DMSO 
1 mM 2-hydroxy-1-napthoic acid, 
500 µM ThDP 
61.4 0.1 2.4 500 µM ThDP, 1% DMSO 
(Derivative) 
1 mM 6-hydroxy-2-napthoic acid 56.8 4.6 -2.6 1% DMSO (Derivative) 
100 µM 6-hydroxy-2-napthoic acid, 
500 µM ThDP 
62.1 0.8 2.8 500 µM ThDP, 1% DMSO 
(Derivative) 
1 mM 6-hydroxy-2-napthoic acid, 
500 µM ThDP 
61.6 0.1 2.7 500 µM ThDP, 1% DMSO 
1 Compared to no additive conditions from the same experiment tray. 
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5.5 Comparisons Between Proteins 
5.5.1 ThDP 
There is no apparent trend observed to be retained between the three proteins interacting with 
ThDP at various concentrations. It is difficult to find direct comparisons between the proteins as 
they exhibit a large variety of effects at each concentration. However, Ec-MenD shows the largest 
Tm changes of the three proteins overall for many of the concentrations in both the situations with 
only ThDP present. For example, at 1000 µM ThDP concentration a Tm increase approximately 
three times higher than either Sau-MenD or Smeg-MenD is observed (9.2 vs 2.7 and 2.3 °C 
respectively, Table 48).  
Table 48: Melting temperature (Tm) comparisons between 5 µM Sau-MenD, Ec-MenD and Smeg-MenD 
from various ThDP conditions. [A dash (-) signifies data unavailable due to an unreadable Tm change. Tm 
and differences are measured in Celsius]. 
Additive(s) 
Tm Diff.  
(Sau-MenD) 
Tm Diff.  
(Ec-MenD) 
Tm Diff.  
(Smeg-MenD) 
50 µM ThDP 0.4 - 0.1 
100 µM ThDP 0.5 9.2 0.1 
250 µM ThDP 0.2 8.55 - 
500 µM ThDP (1) 1.4 8.6 -0.7 
500 µM ThDP (2) 2.8 0.54 0.2 
500 µM ThDP (3) 2.9 0.3 -3.1 
500 µM ThDP (4) 2.5 0.6 0.5 
1000 µM ThDP 2.7 9.2 2.3 
500 µM ThDP, 1 mM TCEP 1.7 - 0.1 
500 µM ThDP, 0.1% DMSO 0.2 1.9 -2.0 
500 µM ThDP, 1% DMSO (2) 0.1 0.5 3.3 
500 µM ThDP, 0.1% DMSO, 
2.5 mM TCEP 
0.0 -0.4 -0.9 
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5.5.2 2-Oxoglutarate 
Addition of 2-oxoglutarate causes significant differences to be seen between the effects on each 
protein (Table 49). Sau-MenD was observed to have a destabilisation trend from 2-oxoglutarate 
binding with 500 µM ThDP presence, with all concentrations of 2-oxoglutarate consistently 
demonstrating this. Conversely, Ec-MenD reacted similarly to as it did with increasing ThDP 
concentration. As 2-oxoglutarate concentration increases as does the Tm for Ec-MenD. These Tm 
increases were considered large increases especially when compared to Smeg-MenD which did 
not appear to display any changes to Tm from 2-oxoglutarate addition. It is more difficult to 
compare the proteins with 2.5 mM TCEP presence in addition to the previous compounds due to 
the incomplete results between proteins (Table 49). One interesting note from the 2-oxoglutarate 
experiments was the finding that without ThDP addition, each protein demonstrated a stabilisation 
effect at a different magnitude, which was almost comparative to the effects seen with ThDP 
presence for all three proteins, albeit the inverse effect for Sau-MenD (2.5 vs 8.3 vs 0.6 °C for 
Sau-MenD, Ec-MenD and Smeg-MenD respectively, Table 49). 
Table 49: Melting temperature (Tm) comparisons between 5 µM Sau-MenD, Ec-MenD and Smeg-MenD 
from various 2-oxoglutarate conditions. [A dash (-) signifies data unavailable due to an unreadable Tm 
change. Tm and differences are measured in Celsius]. 
Additive(s) 
Tm Diff.  
(Sau-MenD) 
Tm Diff.  
(Ec-MenD) 
Tm Diff.  
(Smeg-
MenD) 
1000 µM 2-oxoglutarate 2.5 8.3 0.6 
500 µM ThDP, 50 µM 2-oxoglutarate -1.4 0.6 0.3 
500 µM ThDP, 100 µM 2-oxoglutarate -4.8 0.7 0.0 
500 µM ThDP, 250 µM 2-oxoglutarate -2.9 9.4 0.9 
500 µM ThDP, 500 µM 2-oxoglutarate -3.6 1.6 0.4 
500 µM ThDP, 1000 µM 2-oxoglutarate -1.9 8.4 0.2 
500 µM ThDP, 500 µM 2-oxoglutarate, 
2.5 mM TCEP 
- 6.9 0.1 
500 µM ThDP, 500 µM 2-oxoglutarate, 
0.1% DMSO, 2.5 mM TCEP 
-0.1 - - 
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5.5.3 CHD 
CHD was not a ligand of major focus in this work, but the results provided from the experiments 
warranted further discussion. In a trend like the results observed from the 2-oxoglutarate 
experiments the CHD binding experiments demonstrated destabilisation effects in Sau-MenD, and 
stabilisation effects in Ec-MenD and Smeg-MenD, with a greater stabilisation effect (Tm increase) 
observed in Ec-MenD. This result could be due to the presence of ThDP and 2-oxoglutarate in 
addition to CHD however as the Tm differences were compared to ThDP binding experiments with 
similar concentration this can at least eliminate the possibility that all that is observed is ThDP 
binding effects. 
Table 50: Melting temperature (Tm) comparisons between 5 µM Sau-MenD, Ec-MenD and Smeg-MenD 
from various CHD conditions. [A dash (-) signifies data unavailable due to an unreadable Tm change. Tm 
and differences are measured in Celsius]. 
Additive(s) 
Tm Diff.  
(Sau-MenD) 
Tm Diff.  
(Ec-MenD) 
Tm Diff.  
(Smeg-MenD) 
500 µM ThDP, 
500 µM CHD 
-1.4 0.9 0.3 
500 µM THDP, 
500 µM CHD, 
500 µM 2-oxoglutarate 
-3.8 0.3 -0.1 
 
5.5.4 DHNA 
Due to the lack of data from the Ec-MenD experiments it is difficult to fully compare the three 
proteins and their interactions with DHNA. From what is available without the presence of TCEP 
or any other ligands, all proteins demonstrate a destabilisation effect from DHNA addition to 
varying magnitudes of strength.  
The presence of TCEP in Sau-MenD and Smeg-MenD appears to have a significant stabilisation 
effect, with some exceptions. For Sau-MenD, the exception occurs at 50 µM DHNA concentration, 
suggesting that TCEP has more difficulty at keeping DHNA reduced at higher concentrations, 
whereas for Smeg-MenD this exception occurs at 30 µM DHNA, but is followed by Tm increase 
at 50 and 100 µM. Disregarding these exceptions, TCEP appears to be a suitable reducing agent 
for the use with DHNA as it clearly does interact with the allosteric binder to have some effect. 
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ThDP presence appears to amplify the destabilisation effect observed from DHNA without TCEP 
presence for Sau-MenD, while in Smeg-MenD the effect of ThDP is unpredictable, as seen from 
the varied range of stabilisation and destabilisation effects (Table 51). TCEP presence counteracts 
this amplified destabilisation effect for Sau-MenD, resulting in a lower Tm increase than seen 
without ThDP presence but still a stabilisation effect. Smeg-MenD instead is observed to have only 
stabilisation effects, with a similar magnitude of Tm increase at 100 µM DHNA as seen without 
TCEP presence.  
Presence of 2-oxoglutarate retains the destabilisation effect previously observed upon Sau-MenD, 
with a newfound Tm increase similarly observed for Smeg-MenD. This is still observed with the 
addition for 2.5 mM TCEP for Smeg-MenD, however inconclusive results for Sau-MenD do not 
allow for a conclusion to be made. Overall, DHNA experiments involving the MenD proteins 
require a large amount of further experimentation, with more consideration involving the buffer 
contents and the reaction conditions to determine if the experimental technique can provide usable 
results for future work. 
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Table 51: Melting temperature (Tm) comparisons between 5 µM Sau-MenD, Ec-MenD and Smeg-MenD 
from various DHNA conditions. [A dash (-) signifies data unavailable due to an unreadable Tm change. Tm 
and differences are measured in Celsius]. 
Additive(s) 
Tm Diff.  
(Sau-MenD) 
Tm Diff.  
(Ec-MenD) 
Tm Diff.  
(Smeg-MenD) 
5 µM DHNA - - 0.5 
10 µM DHNA -2.8 -0.19 -29.3 
20 µM DHNA -3.2 -1.7 -32.7 
30 µM DHNA -1.9 -2.4 -25.8 
50 µM DHNA -4.9 -3.1 -29.4 
100 µM DHNA -4.0 -1.5 -24.4 
5 µM DHNA, 2.5 mM TCEP 1.6 - 2.2 
10 µM DHNA, 2.5 mM TCEP 1.0 - 1.6 
20 µM DHNA, 2.5 mM TCEP -0.2 - 2.7 
30 µM DHNA, 2.5 mM TCEP 0.8 - -14.9 
50 µM DHNA, 2.5 mM TCEP -2.8 - 2.3 
100 µM DHNA, 2.5 mM TCEP - -19.7 2.8 
5 µM DHNA, 500 µM ThDP -3.7 0.2 -6.0 
10 µM DHNA, 500 µM ThDP -5.0 0.36 0.8 
50 µM DHNA, 500 µM ThDP - 0.09 -10.0 
100 µM DHNA, 500 µM ThDP -6.0 0.5 23.3 
5 µM DHNA, 500 µM ThDP, 2.5 mM TCEP -0.1 - 0.2 
10 µM DHNA, 500 µM ThDP, 2.5 mM TCEP 0.1 - 1.6 
50 µM DHNA, 500 µM ThDP, 2.5 mM TCEP 0.1 - 1.5 
100 µM DHNA, 500 µM ThDP, 2.5 mM TCEP 1.8 - 29.6 
5 µM DHNA, 500 µM ThDP, 500 µM 2-
oxoglutarate 
-4.2 - -3.2 
10 µM DHNA, 500 µM ThDP, 500 µM 2-
oxoglutarate 
-2.9 5.8 -0.2 
50 µM DHNA, 500 µM ThDP, 500 µM 2-
oxoglutarate 
-4.5 0.5 -15.5 
5 µM DHNA, 500 µM ThDP, 500 µM 2-
oxoglutarate, 2.5 mM TCEP 
1.1 - -7.1 
10 µM DHNA, 500 µM ThDP, 500 µM 2-
oxoglutarate, 2.5 mM TCEP 
- - -3.9 
50 µM DHNA, 500 µM ThDP, 500 µM 2-
oxoglutarate, 2.5 mM TCEP 




NiCl2 experiments failed to provide accurate Tm readings for Ec-MenD and Smeg-MenD through 
the use of DSF. This likely reflects the large detrimental effect of certain metal ions, including 
Ni2+ on MenD stability and activity (e.g. Ni2+ abolishes Mtb-MenD activity).  
Sau-MenD displayed almost no Tm shift with the alternative metals MnCl2 and CaCl2 during 
experimental work. Ec-MenD and Smeg-MenD however, displayed major changes under the 
influence of both of these metals, with CaCl2 having a significantly greater effect upon the Tm of 
Ec-MenD than Smeg-MenD. The presence of ThDP in both cases reduced this effect upon the Tm 
substantially, suggesting interactions between the metal ion and ThDP before protein interaction. 
As magnesium ions were present in the protein buffer at 1 mM this was not a fully controlled metal 
addition experiment and further experiments could remove all metals prior to doing DSF with 
different metals.  
Table 52: Melting temperature (Tm) comparisons between 5 µM Sau-MenD, Ec-MenD and Smeg-MenD 
from various Metal conditions. [A dash (-) signifies data unavailable due to an unreadable Tm change. Tm 
and differences are measured in Celsius]. 
Additive(s) 
Tm Diff.  
(Sau-MenD) 
Tm Diff.  
(Ec-MenD) 
Tm Diff.  
(Smeg-MenD) 
5 mM MnCl2 -0.3 3.0 3.6 
5 mM MnCl2, 500 µM ThDP 0.4 -0.9 -0.1 
5 mM CaCl2 0.3 8.31 3.6 
5 mM CaCl2, 500 µM ThDP -0.1 0.89 1.6 
5 mM NiCl2 -6.9 - - 
5 mM NiCl2, 500 µM ThDP -5.9 -12.5 - 
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5.5.6 Potential Inhibitors 
The main inhibitors of interest from this work as identified in sections 4.2.7, 4.3.7 and 4.4.7 were 
found to be 2-napthoic acid, 2-hydroxy-1-napthoic acid, 6-hyroxy-2-napthoic acid, 1-hydroxy-2-
napthoic acid, p-phenylene diacetic acid, and monobutyl phthalate. While none of these 
compounds was found to have commonalities between all three proteins, inhibitors such as p-
phenylene diacetic acid and 2-hydroxy-1-napthoic acid were found to have effects in 2 or more of 
the proteins and as such are of greater interest for further testing. 
2-Hydroxy-1-napthoic acid is potentially the most interesting of the inhibitors, as it demonstrates 
significantly different results dependent upon both the protein it is interacting with and the 
presence of ThDP. Sau-MenD demonstrates a destabilisation effect in all cases, with the highest 
change found with 1 mM concentration and 500 µM ThDP presence. Smeg-MenD however, has 
high stabilisation effects at all concentrations and regardless of ThDP presence, highlighting a 
major difference in interactions between MenD enzymes. Perhaps the most interesting is Ec-
MenD, as it demonstrates stabilisation effects in the absence of ThDP and destabilisation effects 
while in the presence of ThDP. It should also be noted that these destabilisation effects are greater 
than the stabilisation effects produced, suggesting a potential conformational change in the protein 
with ThDP presence. 
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Table 53: Melting temperature (Tm) comparisons between 5 µM Sau-MenD, Ec-MenD and Smeg-MenD 
from various Potential Inhibitor conditions. [A dash (-) signifies data unavailable due to an unreadable Tm 
change. Tm and differences are measured in Celsius]. 
Additive(s) 
Tm Diff.  
(Sau-MenD) 
Tm Diff.  
(Ec-MenD) 
Tm Diff.  
(Smeg-MenD) 
100 µM 5-hydroxyinole carboxylic acid -2.4 0.1 - 
1 mM 5-hydroxyinole carboxylic acid - -0.4 - 
100 µM 5-hydroxyinole carboxylic acid, 500 
µM ThDP 
- 0.8 - 
1 mM 5-hydroxyinole carboxylic acid, 500 µM 
ThDP 
- 0.5 - 
100 µM 1-hydroxy-2-napthoic acid -0.8 0.5 - 
1 mM 1-hydroxy-2-napthoic acid -1.0 - -1.9 
100 µM 1-hydroxy-2-napthoic acid, 500 µM 
ThDP 
-1.0 0.9 1.6 
1 mM 1-hydroxy-2-napthoic acid, 500 µM 
ThDP 
-0.8 1.1 2.3 
100 µM p-phenylene diacetic acid -0.9 0.4 - 
1 mM p-phenylene diacetic acid -0.6 -32.7 3.4 
100 µM p-phenylene diacetic acid, 500 µM 
ThDP 
-0.8 0.6 3.4 
1 mM p-phenylene diacetic acid, 500 µM 
ThDP 
0.1 0.5 3.3 
100 µM monobutyl phthalate -1.1 0.7 - 
1 mM monobutyl phthalate -0.6 0.7 2.0 
100 µM monobutyl phthalate, 500 µM ThDP -0.5 0.6 3.2 
1 mM monobutyl phthalate, 500 µM ThDP -0.3 0.5 2.6 
100 µM 2-napthtoic acid -1.5 0.7 2.3 
1 mM 2-napthtoic acid 1.2 0.5 1.6 
100 µM 2-napthtoic acid, 500 µM ThDP -1.2 0.6 2.8 
1 mM 2-napthtoic acid, 500 µM ThDP - 0.3 - 
100 µM 2-hydroxy-1-napthoic acid -0.3 0.7 2.1 
1 mM 2-hydroxy-1-napthoic acid -0.6 0.5 1.4 
100 µM 2-hydroxy-1-napthoic acid, 500 µM 
ThDP 
-0.3 -1.3 3.1 
1 mM 2-hydroxy-1-napthoic acid, 500 µM 
ThDP 
-1.6 -1.4 2.4 
100 µM 6-hydroxy-2-napthoic acid - 0.4 - 
1 mM 6-hydroxy-2-napthoic acid -0.8 0.4 -2.6 
100 µM 6-hydroxy-2-napthoic acid, 500 µM 
ThDP 
-0.3 0.6 2.8 
1 mM 6-hydroxy-2-napthoic acid, 500 µM 
ThDP 





Objectives of this Work 
This work’s purpose was to further the characterisation and understanding of the interactions of 
several MenD enzymes from different species. These enzymes (Smeg-MenD, Ec-MenD and Sau-
MenD) were selected to discover more information about the pervasiveness of the allosteric site 
identified in the Mtb-MenD enzyme, while also providing useful results pertaining to the inhibition 
of this essential enzyme in the various species. There were three specific objectives for this work; 
(1) expressing and purifying Ec-MenD and a new TEV cleavable construct of Smeg-MenD in 
quantities large enough for further work, (2) using these two enzymes in addition to Sau-MenD in 
IFQ experiments to analyse known ligand interactions across enzymes, and (3) the use of these 
three enzymes in DSF experiments to analyse interactions with both known ligands and a set of 
known potential inhibitor candidates. 
Discoveries of this Work 
The purification of Ec-MenD in a large enough quantity and to a high enough purity was a 
resounding success in this work, which was completed without any apparent inconveniences 
throughout. The purification of this new construct of Smeg-MenD was also a success, which also 
provided more information in the techniques required to successfully cleave the His-tag from the 
protein. This purification requires specific dialysis conditions to be successful and demonstrated a 
high degree of purity in the final result.  
The IFQ experiments while not appearing to show any commonality between all three proteins did 
provide further insight into the interactions of these proteins with their known ligands. Due to the 
presence of bimodal and monomodal binding that varied between each MenD enzyme, direct 
comparisons cannot be made. However it can be noted that in most conditions, the binding of these 
known ligands to the MenD enzymes were of similar magnitude to one another.  
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DSF provided clearer comparisons between the three MenD enzymes, however this is an area that 
requires further work due to the number of inconclusive results. Similar to the IFQ experiments, 
binding trends of additives did not seem to be the same between the three MenD species, however 
the differences in interactions from these additives provides a greater understanding than the 
similarities would. One universal trend observed however was in the interactions with DHNA, 
with all three proteins demonstrating a destabilisation effect at all concentrations tested. This effect 
varied between the species, with Smeg-MenD experiencing the greatest effect. However, this result 
does suggest some common interactions between all MenD species. In addition, at least three of 
the potential inhibitors investigated in this work demonstrated their ability to have an effect on the 
activity of MenD enzymes, providing an opportunity to refine and explore further. 
Future Work 
In addition to further investigation into at least two major potential inhibitors of interest (p-
phenylene diacetic acid and 2-hydroxy-1-napthoic), many of the IFQ and DSF experiments 
provided inconclusive results which require more work to provide tangible results. The first port 
of call would be to focus upon these experiments which did not work the way we hoped and to do 
replicates of the ones that showed interesting results. Following this, optimisation of the MenD 
enzyme conditions is required. The metal ions used in this work (MgCl2) may not have been the 
ideal metal for all MenD enzymes, and as such adjusting this could change many of the results 
observed. Finally, expansion of the MenD species investigated would help us to understand this 





Protein sequence alignment experiment highlighting conserved residue between Mtb-MenD, Ec-
MenD, Smeg-MenD and Sau-MenD. The alignment was conducted using Clustal omega and the 
highlighting using Clustal X highlighting. This colour scheme highlights hydrophobic residues in 
blue, positively charged in red, negatively charged in magenta, polar residues in green, cysteines 
in pink, glycines in orange, prolines in yellow and aromatic residues in cyan. The sequences are 





DSF experiments for Ec-MenD involving DHNA with additional additives. These results were too 
inconclusive to be included in the final results and suggest further experimentation needed upon 
Ec-MenD and its DHNA interactions. 






























DSF experiments for Smeg-MenD involving DHNA with additional additives. These results were 
too inconclusive to be included in the final results and suggest further experimentation needed 
upon Smeg-MenD and it’s DHNA interactions. 
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